Embed Size (px)
Citation preview
Bibliography
224
Chapter 7
Bibliography
1. Addison WLT. The use of sodium chloride, potassium chloride, sodium
bromide and potassium bromide in cases of arterial hypertension which are
amenable to potassium chloride. Can Med Assoc J 1928; l8l (28): 281- 285.
2. Aderounmu AH and Salako LA. Plasma and erythrocyte cations and
permeability of the erythrocyte membrane to cations in essential
hypertension. Afr J Med Sc 1979; 8(1-2): 45-49.
3. Agachan B, Isbir T, Yilmaz H, Akoglu E. Angiotensin converting enzyme
I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor
A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol
Med 2003; 35(6):545- 549.
4. Agarwal A, Williams GH, Fisher ND. Genetics of human hypertension.
Trends Endocrinol Metab 2005; 16:127–133.
5. Agarwal S, Singh VP, Tewari S, Singha N, Ramesh V, Agarwal S, Gilmour
A, Mastana S. Angiotensin – converting enzyme gene polymorphism in
coronary artery disease in north India. Indian Heart J 2004; 56(1): 44 – 46.
6. Agarwal SK. Chronic kidney disease and its prevention in India. Kidney Int
Suppl 2005; 98: S41-S45.
7. Agema WRP, de Maat MPM, Zwinderman AH, Kastelein JJP, Rabelink TJ,
van Boven AJ, Feskens EJM, Boer JMA, vander Wall EE, Jukema JW. An
integrated evaluation of endothelial constitutive nitric oxide synthase
polymorphisms and coronary artery disease in men. Clin Sci 2004; 107:
255-261.
8. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene
polymorphism in cardiovascular disease: meta-analyses of small and large
studies in whites. Arterioscler Thromb Vasc Biol 2000; 20: 484–492.
9. Ahlawat SK, Singh MM, Kumar R, Kumari S, Sharma BK. Time trends in
the prevalence of hypertension and associated risk factors in Chandigarh. J
Indian Med Assoc 2002; 100(9); 547 – 552.
Bibliography
225
10. Akpa MR, Agomouh DI, Alasia DD. Lipid profile of healthy adult Nigerians
in Port Harcourt, Nigeria. Niger J Med 2006; 15(2): 137-140.
11. Alderman M, McCarron DA, Petiti DB, Freedman D, Bartlett C, Hooper L,
Ebrahim S, Sacks FM, Proschan MA, Svetkey FP. The DASH-Sodium
Collaborative Research Group Dietary sodium and blood pressure. N Engl J
Med 2001; 344(22): 1716-1719.
12. Altshuler D, Kruglyak L, Lander E. Genetic polymorphism and disease. N
Eng J Med 1998; 338(22): 1626.
13. Amant C, Hamon M, Bauters C, Richard F, Helbecque N, McFadden EP,
Escudero X, Lablanche JM, Amouyel P, Bertrand ME. The angiotensin II
type 1 receptor gene polymorphism is associated with coronary artery
vasoconstriction. J Am Coll Cardiol 1997; 29(3): 486 – 490.
14. Ambard L and Beaujard E.Causes de l'hypertension arterielle. Arch Gen
Med 1904; 1:520.
15. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of
angiotensin II and norepinephrine on blood pressure electrolyte balance and
aldosterone and cortisol secretion in normal man and in cirrhosis with
ascites. J Clin Invest 1965; 44(7):1171 - 1186.
16. Anand MP. Prevalence of hypertension amongst Mumbai executives. J
Assoc Phys Ind 2000; 48: 1200–1201.
17. Anastos K, Charney P, Charon RA, Cohen E, Jones CY, Marte C, Swiderski
DM, Wheat ME, Williams S. Hypertension in women: what is really
known? The Women’s Caucus, Working Group on Women’s Health of the
Society of General Internal Medicine. Ann Intern Med. 1991; 115(4): 287–
293.
18. Andersson B, Blange I, Sylven C. Angiotensin-II type 1 receptor gene
polymorphism and long-term survival in patients with idiopathic congestive
heart failure. Eur J of Heart Fail 1999; (1): 363-369.
19. Antonellis A, Rogus JJ, Canani LH, Makita Y, Pezzolesi MG, Nam M, Ng
D, Moczulski D, Warram JH, Krolewski AS. A method for developing high
density SNP maps and its application at the type 1 angiotensin II receptor
(AGTR1) locus. Genomics 2002; 79(3):326–332.
Bibliography
226
20. Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C,
Panagiotakos D, Tentolouris C, Marinou K, Koumallos N, Stefanadis C.
Genetic polymorphism on endothelial nitric oxide synthase affects
endothelial activation and inflammatory response during the acute phase of
myocardial infarction. J Am Coll Cardiol 2005; 46(6): 1101-1109.
21. Anvekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Roulau
JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S,
Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction
and cardiovascular outcomes after myocardial infarction. N Engl J Med
2004; 351(13):1285-1295.
22. Arngrimsson R, Purandare S, Connor M, Walker JJ, Bjornsson S, Soubrier
F, Kotelevtsev YV, Geirsson RT, Bjornsson H. Angiotensinogen: a
candidate gene involved in preeclampsia? Nat Genet 1993; 4(2):114 – 115.
23. Ashton N and Balment RJ. Sexual dimorphism in renal function and
hormonal status of New Zealand genetically hypertensive rats. Acta
Endocrinol (Copenh) 1991; 124: 91–97.
24. Atwood LD, Kammerer CM, Samollow PB, Hixson JE, Shade RE,
MacCluer JW. Linkage of Essential Hypertension to the Angiotensinogen
Locus in Mexican Americans. Hypertension 1997; 30(3):326-330.
25. Babunova NB, Minushkina LO, Zateishchikov DA, Sidorenko BA, Nosikov
VV. Association of the T174M and M235T polymorphisms of the
angiotensinogen gene with myocardial ischemia in the Russian population of
the city of Moscow. Mol Biol (Mosk) 2003; 37(1): 57-60.
26. Bailey MA, Paterson JM, Hadoke PW, Wrobel N, Bellamy CO, Brownstein
DG, Seckl JR, Mullins JJ. A switch in the mechanism of hypertension in the
syndrome of apparent mineralocorticoid excess. J Am Soc Nephrol 2008; 19
(1): 47–58.
27. Barbalic M, Skaric-Juric T, Cambien F, Barbaux S, Poirier O, Turek S,
Vrhovski-Hebrang D, Cubrilo-Turek M, Rudan I, Rudan P, Narancic NS.
Gene polymorphisms of the renin-angiotensin system and early development
of hypertension. Am J Hypertens 2006; 19(8):837- 842.
Bibliography
227
28. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffrey S,
Ogunlesi AO, Sagnella GA. Angiotensin Converting Enzyme
Insertion/Deletion Polymorphism: association with ethnic origin. J
Hypertens 1994; 12(8): 955-957.
29. Barley J, Blackwood A, Miller M, Markandu ND, Carter ND, Jeffery S,
Cappuccio FP, MacGregor GA, Sagnella GA. Angiotensin converting
enzyme gene I/ D polymorphism, blood pressure and the rennin-angiotensin
system in Caucasian and Afro-Caribbean peoples. J Hum Hypertens 1996;
10(1): 31-35.
30. Baudin B. Angiotensin I converting enzyme gene polymorphism and drug
response. Clin Chem Lab Med 2000; 38(9): 853 – 856.
31. Behera D, Uppal R, Majumdar S. Urinary levels of nicotinine and cotinine
in tobacco users. Indian J Med Res 2003; 118: 129-133.
32. Behravan J, Naghibi M, Mazloomi MA, Hassay M. Polymorphism of
angiotensin II type I receptor gene in essential hypertension in Iranian
population. DARU J of Pharmaceutical Sciences 2006; 14(2): 82 – 86.
33. Bell J. Determination of glycyrrhizic acid in licorice extracts and chewing
tobaccos. Tobacco Science 1980; 24: 126-129.
34. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, Lacolley P,
Poirier O, Topouchian J, Asmar R. Influence of the angiotensin II type 1
receptor gene polymorphism on the effects of perindopril and nitrendipine
on arterial stiffness in hypertensive individuals. Hypertension 1996;
28(6):1081-1084.
35. Benjafield AV and Morris BJ. Association analyses of endothelial nitric
oxide synthase gene polymorphisms in essential hypertension. Am J
Hypertens 2000; 13(9): 994-998.
36. Benowitz NL and Jacob P 3rd
. Intravenous nicotine replacement suppresses
nicotine intake from cigarette smoking. J Pharmacol Exp Ther 1990; 254(3):
1000-1005.
37. Benowitz NL, Jacob P 3rd
, Yu L. Daily use of smokeless tobacco: systemic
effects. Ann Intern Med 1989; 111(2): 112-116.
Bibliography
228
38. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd
. Nicotine absorption and
cardiovascular effects with smokeless tobacco use: comparison with
cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44(1):23-28.
39. Blair SN, Goodyear NN, Gibbons LW, Cooper KH. Physical fitness and
incidence of hypertension in healthy normotensive men and women. JAMA.
1984; 252(4): 487-490.
40. Blaustein MP and Hamlyn JM. Pathogenesis of essential hypertension: A
link between dietary salt and high blood pressure. Hypertens 1991;
18(5Suppl): III 184-195.
41. Bloem LJ, Foroud TM, Ambrosius WT, Hanna MP, Tewksbury DA, Pratt
JH. Association of the angiotensinogen gene to serum angiotensinogen in
blacks and whites. Hypertension 1997; 29(5): 1078-1082.
42. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum
angiotensinogen concentration and variants of the angiotensinogen gene in
white and black children. J Clin Invest 1995; 95(3): 948–953.
43. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R,
Georgiades A, Craighead LW, Tweedy D, Feinglos M, Appelbaum M,
Hayano J, Hinderliter A. Exercise and weight loss reduce blood pressure in
men and women with mild hypertension: effects on cardiovascular,
metabolic and hemodynamic functioning. Arch Intern Med 2000; 160(13):
1947-1958.
44. Bolinder GM, Ahlborg BO, Lindell JH. Use of smokeless tobacco: blood
pressure elevation and other health hazards found in a large-scale population
survey. J Intern Med 1992; 232(4): 327–334.
45. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret
L, Cambien F, Corvol P, Soubrier F. Angiotensin II type 1 receptor gene
polymorphisms in human essential hypertension. Hypertension 1994; 24(1):
63– 69.
46. Borah PK, Shankarishan P, Ahmed G, Mahanta J. Polymorphism of
angiotensin converting enzyme (insertion/deletion) and endothelial nitric
oxide synthase (intron 4ab) genes in a population from north-east India. J
Genet 2011: 90(3); e105–e109.
Bibliography
229
47. Borst JG and Borst DeGA. Hypertension explained by Starling's theory of
circulatory homeostasis. Lancet 1963; 1(7283): 677 - 682.
48. Boucher BJ and Mannan N. Metabolic effects of the consumption of Areca
catechu. Addict Biol 2002; 7(1): 103 – 110.
49. Brand E, Chatelain N, Keavney B, Caulfield M, Citterio L, Connell J,
Grobbee D, Schmidt S, Schunkert H, Schuster H, Sharma AM, Soubrier F.
Evaluation of the angiotensinogen locus in human essential hypertension: a
European study. Hypertension 1998; 31(3): 725-729.
50. Bravo EL. Metabolic factors and the sympathetic nervous system. Am J
Hypertens 1989; 2(12): 339S-344S.
51. Bray GA. Risks of obesity. Endocrinol Metab Clin North Am 2003; 32(4):
787-804.
52. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH,
Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study
Investigators. Effects of losartan on renal and cardiovascular outcomes in
patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):
861–869.
53. Bulpitt CJ, Shipley MJ, Semmence A. Blood pressure and plasma sodium
and potassium. Clin Sci (Lond) 1981; 61 (Suppl 7): S85–S87.
54. Burl VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan
MJ, Labarthe D. Prevalence of hypertension in the US adult population.
Results from the Third National Health and Nutrition Examination Survey,
1988 –1991. Hypertension. 1995; 25(3): 305–313.
55. Busjahn A, Knoblauch H, Knoblauch M, Bohlender J, Menz M, Faulhaber
HD, Becker A, Schuster H, Luft FC. Angiotensin-converting enzyme and
angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A
Twin Study. Hypertension 1997; 29(1): 165-170.
56. Butler R, Morris AD, Burchell B, Struthers AD. DD angiotensin-converting
enzyme gene polymorphism is associated with endothelial dysfunction in
normal humans. Hypertension 1999; 33(5): 1164–1168.
57. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A,
Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey
Bibliography
230
RM. Resistant hypertension: diagnosis, evaluation and treatment. A
scientific statement from the American Heart Association Professional
Education Committee of the Council for High Blood Pressure Research.
Hypertension 2008; 51(6): 1403-1419.
58. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial
NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide
dilator mechanism appears abnormal. J Hypertens 1992; 10(9): 1025-1031.
59. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G,
Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc – Gelas F, Soubrier
F. Deletion polymorphism in the gene for angiotensin converting enzyme is
a potent risk factor for myocardial infarction. Nature 1992; 359(6396): 641–
644.
60. Cappucio FP and MacGregor GA. Does potassium supplementation lower
blood pressure? A meta-analysis of published trials. J Hypertens 1991; 9(5):
465-473.
61. Carman WJ, Barrett-Connor E, Sowers M, Khaw KT. Higher risk of
cardiovascular mortality among lean hypertensive individuals in Tecumseh,
Michigan. Circulation 1994; 89(2): 703-711.
62. Carretero OA and Oparil S. Essential Hypertension. Part-I: definition and
etiology. Circulation 2000; 101(3): 329-335.
63. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric
oxide synthase genotype and ischemic heart disease: meta-analysis of 26
studies involving 23028 subjects. Circulation 2004; 109(11): 1359-1365.
64. Castellano M, Glorioso N, Cusi D, Sarzani R, Fabris B, Opocher G, Zoccali
C, Golin R, Veglio F, Volpe M, Mantero F, Fallo F, Rossi GP, Barlassina C,
Tizzoni L, Filigheddu F, Giacche M, Rossi F, Molecular Genetic Study
Group of the Italian Society of Hypertension. Genetic polymorphism of the
renin-angiotensin-aldosterone system and arterial hypertension in the Italian
population: the GENIPER Project. J Hypertens 2003; 21(10): 1853–1860.
65. Castelli WP and Anderson K. A population at risk. Prevalence of high
cholesterol levels in hypertensive patients in the Framingham study. Am J
Med 1986; 80(2A): 23-32.
Bibliography
231
66. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J
1986; 112(2): 432-437.
67. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark
AJL. Linkage of the angiotensinogen gene to essential hypertension. N Eng
J Med 1994; 330(23): 1629-1633.
68. Caulfield M, Lavender P, Newell-Price J, Farall M, Kamdar S, Daniel H,
Lawson M, De Freitas P, Fogarty P, Clark AJ. Linkage of the
angiotensinogen gene locus to human essential hypertension in African
Caribbeans. J Clin Invest 1995; 96(2): 687-692.
69. Channon KM, Qian H, George SE. Nitric oxide synthase in atherosclerosis
and vascular injury: insights from experimental gene therapy. Arterioscler
Thromb Vasc Bio 2000; 20(8): 1873-1881.
70. Chen YF and Meng QC. Sexual dimorphism of blood pressure in
spontaneously hypertensive rats is androgen dependent. Life Sci 1991;
48(1): 85–96.
71. Chiang FT, Chern TH, Lai ZP, Tseng CD, Hsu KL, Lo HM, Tseng YZ. Age
and gender dependent association of the angiotensin-converting enzyme
gene with essential hypertension in a Chinese population. J Hum Hypertens
1996; 10(12): 823-826.
72. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV,
Pease LJ, Wong PC, Wexler RR, Johnson AL, Timmermans PBMWM.
Identification of angiotensin II receptor subtypes. Biochem Biophys Res
Commun 1989; 165(1): 196-203.
73. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr,
Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National
Heart, Lung and Blood Institute; Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pressure; National High
Blood Pressure Eduation Program Coordinating Committee. The seventh
report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA
2003; 289(19): 2560-2572.
Bibliography
232
74. Chobanian AV. Clinical practice. Isolated systolic hypertension in the
Elderly. N Eng J Med 2007; 357(8): 789-796.
75. Chu NS. Neorological aspects of areca and betel chewing. Addict Biol 2002;
7(1): 111 – 114.
76. Chung FM, Shieh TY, Yang YH, Chang DM, Shin SJ, Tsai JC, Chen TH,
Tai TY, Lee YJ. The role of angiotensin-converting enzyme gene
insertion/deletion polymorphism for blood pressure regulation in areca nut
chewers. Transl Res 2007; 150(1): 58–65.
77. Cobb S and Rose RM. Hypertension, peptic ulcer and diabetes in air traffic
controllers. JAMA 1973; 224(4): 489-492.
78. Cohen P, Badouaille G, Gimenez-Roqueplo AP, Mani JC, Guyene TT,
Jeunemaitre X, Menard J, Corvol P, Pau B, Simon D. Selective
recognition of M235T angiotensinogen variants and their determination in
human plasma by monoclonal antibody-based immunoanalysis. J Clin
Endocrinol Metab 1996; 81 (10): 3505-3512.
79. Collis T, Devereux RB, Roman MJ, de Simon G, Yeh J, Howard BV,
Fabsitz RR, Welty TK. Relations of stroke volume and cardiac output to
body composition: the strong heart study. Circulation 2001; 103(6): 820-
825.
80. Colombo MG, Andreassi MG, Paradossi U, Botto N, . Manfredi S, Masetti S,
Rossi G, Clerico A, Biagini A. Evidence for association of a common
variant of the endothelial nitric oxide synthase gene G1u298Asp
polymorphism; to the presence, extent, and severity of coronary artery
disease. Heart 2002; 87(6): 525-528.
81. Conte G, Dal Canton A, Terribile M, Cianciaruso B, Di Minno G, Pannain
M, Russo D, Andreucci VE. Renal handling of urea in subjects with
persistent azotemia and normal renal function. Kidney Int 1987; 32(5):721-
727.
82. Cooke JP and Dzau VJ. Nitric oxide synthase: role in the genesis of vascular
disease. Annu Rev Med 1997; 48: 489–509.
83. Corvol P and Jeunemaitre X. Molecular Genetics of Human Hypertension:
role of angiotensinogen. Endocr Rev 1997; 18(5): 662–677.
Bibliography
233
84. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-
converting enzyme in human circulating mononuclear cells: genetic
polymorphism of expression in T-lymphocytes. Biochem J 1993; 290(1):
33–40.
85. Criqui MH, Barrett-Connor E, Holdbrook MJ, Austin M, Turner JD.
Clustering of cardiovascular disease risk factors. Prev Med 1980; 9(4): 525-
533.
86. Criqui MH, Cowan LD, Heiss G, Haskell WL, Laskarzewski PM,
Chambless LE. Frequency and clustering of non lipid coronary risk factors
in dyslipoproteinemia. The Lipid Research Clinics Program Prevalence
Study. Circulation 1986; 73(suppl I): I40-I50.
87. Crofton JT, Ota M, Share L. Role of vasopressin, the renin-angiotensin
system, and sex in Dahl salt-sensitive hypertension. J Hypertens 1993;
11(10): 1031–1038.
88. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and
epinephrine release and adrenergic mediation of smoking-associated
hemodynamic and metabolic events. N Engl J Med 1976; 295(11): 573–577.
89. Dahl LK. Salt and hypertension. Am J Cl Nutrition 1972; 25(2): 231 - 244.
90. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR,
Riegger GA, Schunkert H. Angiotensin-converting enzyme in the human
heart. Effect of the deletion/insertion polymorphism. Circulation 1995;
92(6): 1387–1388.
91. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International
Union of Pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev
2000; 52(3): 415-472.
92. de Simone G, Devereux RB, Chinali M, Roman MJ, Best LG, Welty TK,
Lee ET, Howard BV; Strong Heart Study Investigators. Risk factors for
arterial hypertension in adults with initial optimal blood pressure: the Strong
Heart Study. Hypertension 2006; 47(2): 162-167.
93. de Simone G, Roman MJ, Daniels SR, Mureddu G, Kimball TR, Greco R,
Devereux RB. Age-related changes in total arterial capacitance from birth to
Bibliography
234
maturity in a normotensive population. Hypertension 1997; 29(6): 1213–
1217.
94. de Wardener HE, He FJ, MacGregor GA. Plasma sodium and hypertension.
Kidney Int 2004; 66(6): 2454–2466.
95. Deepa R, Shanthirani CS, Pradeepa R, Mohan V. Is the ‘rule of halves’ in
hypertension still valid? Evidence from the Chennai Urban Population
Study. J Assoc Physicians India 2003; 51: 153-157.
96. Devlin AM, Brosnan MJ, Graham D, Morton JJ, McPhaden AR, McIntyre
M, Hamilton CA, Reid JL, Dominiczak AF. Vascular smooth muscle cell
polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in
vivo. Am J Physiol 1998; 274(1): H52-H59.
97. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV,
Williams B, Ford GA. Lifestyle interventions to reduce raised blood
pressure: a systematic review of randomized controlled trials. J Hypertens
2006; 24(2): 215-233.
98. Diez J, Laviades C, Orbe J, Zalba G, Lopez B, Gonzalez A, Mayor G,
Paramo JA, Beloqui O. The A1166C polymorphism of the AT1 receptor
gene is associated with collagen type I synthesis and myocardial stiffness in
hypertensives. J Hypertension 2003; 21(11): 2085-2092.
99. Ding PY, Hu OY, Pool PE, Liao W. Does Chinese ethnicity affect the
pharmaco-kinetics and pharmaco-dynamics of angiotensin-converting
enzyme inhibitors? J Hum Hypertens 2000; 14(3): 163 – 170.
100. Drexler H and Hornig B. Endothelial dysfunction in human disease. J Mol
Cell Cardiol 1999; 31(1): 51–60.
101. Duncan JA, Scholey JW, Miller JA. Angiotensin II type 1 receptor gene
polymorphisms in humans: physiology and pathophysiology of the
genotypes. Curr Opin Nephrol Hypertens 2001; 10(1): 111- 116.
102. Dunn AL, Andersen RE, Jakicic JM. Lifestyle physical activity
interventions. History, short- and long-term effects, and recommendations.
Am J Prev Med 1998; 15(4): 398– 412.
103. Duru K, Farrow S, Wang JM, Lockette W, Kurtz T. Frequency of a deletion
polymorphism in the gene for angiotensin converting enzyme is increased in
Bibliography
235
African-Americans with hypertension. Am J Hypertens 1994; 7(8): 759-
762.
104. Dustan HP. Diuretics in the treatment of hypertension. Postgrad Med 1959;
26; 446 – 449.
105. Dwivedi S, Singh G, Agarwal MP. Profile of hypertension in elderly
subjects. J Assoc Physicians India 2000; 48(11): 1047-1049.
106. Dyer AR, Liu K, Walsh M, Kiefe C, Jacobs DR Jr, Bild DE. Ten-year
incidence of elevated blood pressure and its predictors: the CARDIA study.
Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens
1999; 13(1): 13-21.
107. Dzida G, Sobstyl J, Puzniak A, Golon P, Mosiewicz J, Hanzlik J.
Polymorphisms of angiotensin converting enzyme and angiotensin II
receptor type I genes in essential hypertension in a polish population. Med
Sci Monit 2001; 7(6): 1236 – 1241.
108. El-Dorry HA, Pickett CB, MacGregor JS, Soffer RL. Tissue-specific
expression of mRNAs for dipeptidyl carboxypeptidase isoenzymes. Proc
Natl Acad Sci USA 1982; 79(14): 4295– 4297.
109. Erdmann J, Riedel K, Rohde K, Folgmann I, Wienker T, Fleck E, Regitz-
Zagrosek V. Characterization of polymorphisms in the promoter of the
human angiotensin II subtype 1 (AT1) receptor gene. Ann Hum Genet 1999;
63(4): 369-374.
110. Erdos SG and Skidgel RA. Metabolism of Bradykinin by peptidases in
health and disease. In: SG Farmer, ed. Handbook of immunopharmocology:
the kinin system. London: Academic Press 1997: 111 – 141.
111. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure
control on diabetic microvascular complications in patients with
hypertension and type 2 diabetes. Diabetes Care 2000; 23(2): B54–B64.
112. Fasola AF, Martz BL, Helmer M. Plasma renin activity during supine
exercise in offspring of hypertensive parents. J Appl Physiol 1966; 21(6):
1709 - 1712.
113. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, Ruiz-Galdon M,
Espinosa-Caliani S, Aranda-Lara P, Rius-Diaz F, Gaitan-Arroyo MJ, De
Bibliography
236
Teresa-Galvan E, Reyes-Engel A. Both alleles of the M235T polymorphism
of the angiotensinogen gene can be a risk factor for myocardial infarction.
Clin Genet 2001: 60(1): 52–57.
114. Fernandez-Sola J, Nicolas JM, Oriola J, Sacaneella E, Estruch R, Rubin E,
Urbano-Marquez A. Angiotensin converting enzyme gene polymorphism is
associated with vulnerability to alcoholic cardio-myopathy. Inn Intern Med
2002; 137(5): 321 – 326.
115. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic
implications of more than a century of research. J Renin Angiotensin
Aldosterone Syst 2006; 7(1): 3-14.
116. Ferreira SR, Iunes M, Franco LJ, Iochida LC, Hirai A, Vivolo MA.
Disturbances of glucose and lipid metabolism in first and second generation
Japanese-Brazilians. Japanese-Brazilian Diabetes Study Group. Diabetes
Res Clin Pract 1996; 34: S59- S63.
117. Fogelman AM, Schechter I, Seager J, Hokom M, Child JS, Edwards PA.
Malondialdehyde alteration of low density lipoproteins leads to chlesteryl
ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci
USA 1980; 77(4): 2214-2218.
118. Forstermann U, Closs El, Pollock JS, Nakane M, Schwarz P, Gath I,
Kleinert H. Nitric oxide synthase isoenzymes. Characterization, purification,
molecular cloning, and functions. Hypertension 1994; 23(6): 1121-1131.
119. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal
nitric oxide synthesis in essential hypertension. Lancet 1997; 349(9055):
837-842.
120. Fowkes FG, Lee AJ, Hau CM, Cooke A, Connor JM, Lowe GD. Methylene
tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (eNOS)
genes and risks of peripheral arterial disease and coronary heart disease:
Edinburgh Artery Study. Atherosclerosis 2000; 150(1): 179–185.
121. Franklin SS, Gustin W 4th
, Wong ND, Larson MG, Weber MA, Kannel WB,
Levy D. Hemodynamic patterns of age-related changes in blood pressure.
The Framingham Heart Study. Circulation 1997; 96: 308 –315.
Bibliography
237
122. Fries ED. Salt, volume and prevention of hypertension. Circulation 1976;
53(4): 589 - 595.
123. Froment A, Milon H, Gravier C. Relationship of sodium intake and arterial
hypertension. Contribution of geographical epidemiology. Rev Epidemiol
Sante Publique 1979; 27(5 – 6): 437 – 454.
124. Furchgott RF and Zawadski JV. The obligatory role of endothelial cells in
the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;
288(5789): 373 – 376.
125. Furuta H, Guo DF, Inagami T. Molecular cloning and sequencing of the
gene encoding human angiotensin II type I receptor. Biochem Biophys Res
Commun 1992; 183(1): 8-13.
126. Gainer JV, Hunley TE, Kon V, Nadeau JH, Muldowney JA 3rd
, Brown NJ.
Angiotensin II type I receptor polymorphism in African Americans lower
frequency of the C1166 variant. Biochem Mol Biol Int 1997; 43(1): 227-
231.
127. Ganten U, Schroder G, Witt M, Zimmerman F, Ganten D, Stock G. Sexual
dimorphism of blood pressure in spontaneously hypertensive rats: effects of
anti-androgen treatment. J Hypertens 1989; 7(9): 721–726.
128. Gardes J, Bouhnik J, Clauser E, Corvol P, Menard J. Role of
angiotensinogen in blood pressure homeostasis. Hypertesion 1982; 4(2):
185-189.
129. Garland C, Barrett-Connor E, Suarez L, Criqui MH. Isolated systolic
hypertension and mortality after age 60 years. A prospective population
based study. Am J Epidemiol 1983; 118(3): 365- 376.
130. Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of
pair-wise haplotype frequencies: implications for linkage disequilibrium
analyses and a web tool ‘CubeX’. BMC Bioinformatics 2007; 8: 428.
131. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, Trent RJ.
Elite endurance athletes and the ACE I allele: the role of genes in athletic
performance; Hum Genet 1998; 103(1): 48–50.
Bibliography
238
132. Giacchetti G, Turchi F, Boscaro M, Ronconi V. Management of primary
aldosteronism: its complications and their outcomes after treatment. Curr
Vasc Pharmacol 2009; 7 (2): 244–249.
133. Gibbons LW, Blair SN, Cooper KH, Smith M. Association between
coronary heart disease risk factors and physical fitness in healthy adult
women. Circulation. 1983; 67(5): 977 - 983.
134. Gilberts EC, Arnold MJ, Grobbee DE. Hypertension and determinants of
blood pressure with special reference to socio-economic status in a rural
south Indian community. J Epidemiol Community Health 1994; 48(3): 258 –
261.
135. Giner V, Poch E, Bragulat E, Oriola J, Gonzalez D, Coca A, De La Sierra A.
Renin-angiotensin system genetic polymorphisms and salt sensitivity in
essential hypertension. Hypertension 2000; 35(1): 512-517.
136. Girerd X, Hanon O, Mourad JJ, Boutouyrie P, Laurent S, Jeunemaitre X.
Lack of association between renin-angiotensin system, gene polymorphisms,
and wall thickness of the radial and carotid arteries. Hypertension 1998;
32(3): 579-583.
137. Glotov AS, Ivaschenko TE, Obraztsova GI, Nasedkina TV, Baranov VS.
Renin-angiotensin and kinin-bradykinin genes polymorphism effects on
permanent arterial hypertension in children. Mol Biol (Mosk) 2007;
41(1):18-25.
138. Goldbourt U, Holtzman E, Cohen-Mandelzweig L, Neufeld HN. Enhanced
risk of coronary heart disease mortality in lean hypertensive men.
Hypertension 1987; 10(1): 22-28.
139. Gomez RA. Renal disease in Colombia. Ren Fail 2006; 28(8): 643-647.
140. Gould AB and Green D. Kinetics of the human renin and human substrate
reaction. Cardiovasc Res 1971; 5 (1): 86-89.
141. Grassi GM, Somers VK, Renk WS, Abboud FM, Mark AL. Effects of
alcohol intake on blood pressure and sympathetic nerve activity in
normotensive humans: a preliminary report. J Hypertension 1989; 7 (Suppl
6):S20–S21.
Bibliography
239
142. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-
angiotensin system. Circulation 1993; 87(6): 1816–1828.
143. Griffith P. The history of the Indian Tea Industry. London: Weiden &
Nicolson; 1967.
144. Grobbee DE. Methodology of sodium sensitivity assessment. The example
of age and sex. Hypertens 1991; 17(1): I109- I114.
145. Grundy SM. Cholesterol and coronary heart disease. Future directions.
JAMA 1990; 264(23): 3053 – 3059.
146. Gu D, He J, Wu X, Duan X, Whelton PK. Effect of potassium
supplementation on blood pressure in Chinese: a randomized placebo-
controlled trial. J Hypertens 2001; 19(7): 1325-1321.
147. Gui-yan W, Yan-hua W, Qun X, Wei-jun T, Ming-ling G, Jian W, Ming-wu
F, Yong-hong Z. Associations between RAS Gene polymorphisms,
environmental factors and hypertension in Mongolian people. Eur J
Epidemiol 2006; 21(4):287-292.
148. Guo DF, Furuta H, Mizukoshi M, Inagami T. The genomic organization of
human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1994;
200(1): 313–319.
149. Gupta PC and Gupta R. Hypertension prevalence and blood pressure trends
among 99,589 subjects in Mumbai, India. Indian Heart J 1999; 51: 691.
150. Gupta R, al-Odat NA, Gupta VP. Hypertension epidemiology in India: meta-
analysis of 50 year prevalence rates and blood pressure trends. J Hum
Hypertens 1996; 10(7): 465–472.
151. Gupta R, Gupta VP, Sarna M, Bhatnagar S, Thanvi J, Sharma V, Singh AK,
Gupta JB, Kaul V. Prevalence of coronary heart disease and risk factors in
an urban Indian population: Jaipur Heart Watch-2. Indian Heart J. 2002;
54(1): 59–66.
152. Gupta R, Guptha S, Gupta VP, Prakash H. Prevalence and determinants of
hypertension in the urban population of Jaipur in Western India. J Hypertens
1995a; 13(10): 1193–1200.
Bibliography
240
153. Gupta R, Rastogi S, Panwar RB, Soangra MR, Gupta VP, Gupta KD. Major
coronary risk factors and coronary heart disease epidemic in India. South
Asian J Prev Cardiol 2003; 7(1): 11–40.
154. Gupta R, Sharma AK. Prevalence of hypertension and subtypes in an Indian
rural population: clinical and electrocardiographic correlates. J Hum
Hypertens 1994; 8: 823–829.
155. Gupta R, Sharma SC, Gupta VP, Gupta KD. Smoking and alcohol intake in
a rural Indian population and correlation with hypertension and coronary
heart disease prevalence. J Assoc Physicians India 1995b; 43(4): 253-258.
156. Gupta R. Defining hypertension in the Indian population. Natl Med J India
1997a; 10: 139–143.
157. Gupta R. Meta-analysis of prevalence of hypertension in India. Indian Heart
J 1997b; 49: 43-8.
158. Gupta R. Trends in Hypertension Epidemiology in India. J Hum Hypertens
2004; 18(2): 73-78.
159. Gupta SP, Siwach SB, Moda VK. Epidemiology of hypertension. Based on
total community survey in the urban population of Haryana. India Heart J
1978; 30(6): 315-322.
160. Guyton AC, Coleman TG, Cawley AW, Manning RD Jr, Norman RA,
Ferguson JD: A systems analysis approach to understanding long-range
arterial blood pressure control and hypertension. Circ Res 1974; 35(2): 159 -
176.
161. Guyton AC, Hall JE, Lohmeier TE, Jackson TE, Kastner PR. Blood Pressure
Regulation: basic concepts. Fed Proc 1981; 40(8): 2252-2256.
162. Haapanen N, Miilunpalo S, Vuori I, Oja P, Pasanen P. Association of leisure
time physical activity with the risk of coronary heart disease, hypertension
and diabetes in middle-aged men and women. Int J Epidemiol. 1997; 26(4):
739 - 747.
163. Haddy FJ. Roles of salt, potassium, calcium and natriuretic factors in
hypertension. Hypertension 1991; 18(5 Suppl): 179-183.
Bibliography
241
164. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of
cardiovascular risk factors in confirmed prehypertensive individuals.
Hypertension 1992; 20(1): 38-45.
165. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM.
Dyslipidemia and the risk of incident hypertension in men. Hypertension
2006; 47(1): 45-50.
166. Hamon M, Amant C, Bauters C, Richard F, Helbecque N, Mc Fadden E,
Lablanche JM, Bertrand M, Amouyel P. Association of angiotensin
converting enzyme and angiotensin II type 1 receptor genotypes with left
ventricular function and mass in patients with angiographically normal
coronary arteries. Heart 1997; 77(6): 502-505.
167. Harrap SB, Davison HR, Connor JM, Soubrier F, Corvol P, Fraser R, Foy
CJ, Walt GC. The angiotensin converting enzyme gene and predisposition of
high blood pressure. Hypertension 1993; 21(4): 455-460.
168. Hart C, Ecob R, Smith GD. People, places and coronary heart disease risk
factors: a multilevel analysis of the Scottish Heart Health Study archive. Soc
Sci Med 1997; 45(6): 893-902.
169. Harvey JM and Beevers DG. Biochemical investigation of hypertension.
Ann Clin Biochem 1990; 27(4): 287-296.
170. Hata A, Namikawa C, Sasaki M, Sato M, Nakamura T, Tamura K, Lalouel
JM. Angiotensinogen as a risk factor for essential hypertension in Japan. J
Clin Invest 1994; 93(3): 1285-1287.
171. Hattersley AT and McCarthy MI. What makes a good genetic association
study? Lancet 2005; 366(9493):1315-1323.
172. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide
synthesis increases blood pressure in healthy humans. J Hypertens 1993;
11(12): 1375- 1380.
173. Hazarika NC, Biswas D, Narain K, Kalita HC, Mahanta J. Hypertension and
its risk factors in tea garden workers of Assam. Natl Med J India 2002;
15(2): 63-68.
Bibliography
242
174. Hazarika NC, Biswas D, Narain K, Phukan RK, Kalita HC, Mahanta J.
Differences in blood pressure level and hypertension in three ethnic groups
of north eastern India. Asia Pac J Public Health 2000; 12(2): 71 – 78.
175. Hazarika NC, Narain K, Biswas D, Kalita HC, Mahanta J. Hypertension in
the native rural population of Assam. Natl Med J India 2004; 17(6): 300 –
304.
176. He FJ and MacGregor GA. Effect of a modest salt reduction on blood
pressure: a meta-analysis of randomized trials. Implications for public
health. J Hum Hypertens 2002; 16(11): 761-770.
177. He FJ and MacGregor GA. How far should salt intake be reduced?
Hypertension 2003; 42(6): 1093-1099.
178. He FJ, Markandu ND, Colhart R, Barron J, MacGregor GA. Effect of short-
term supplementation of potassium chloride and potassium citrate on blood
pressure in hypertension. Hypertension 2005a; 45(4): 571-574.
179. He FJ, Markandu ND, Sagnella GA, de Wardener HE, MacGregor GA.
Plasma sodium: ignored and underestimated. Hypertension 2005b; 45(1):
98–102.
180. He J and Whelton PK. Role of sodium reduction in the treatment and
prevention of hypertension. Cirr Opin Cardiol 1997; 12(2): 202-207.
181. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer
JA, Faubert P, Rolin HA, Wang SR. Effects of blood pressure control on
progressive renal disease in blacks and whites: Modification of Diet in Renal
Disease Study Group. Hypertension 1997; 30(3): 428–435.
182. Henrion D, Amant C, Benessiano J, Philip I, Plantefeve G, Chatel D, Hwas
U, Desmont JM, Durand G, Amouyel P, Levy BI. Angiotensin II type 1
receptor gene polymorphism is associated with an increased vascular
reactivity in the human mammary artery in vitro. J Vasc Res 1998; 35(5):
356 –362.
183. Henry PD. Hyperlipidemic arterial dysfunction. Circulation 1990; 81(2):
697-669.
184. Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de
Leeuw, PW, Kroon AA. Effects of ACE I/D and AT1R-A1166C
Bibliography
243
polymorphisms on blood pressure in a healthy normotensive primary care
population: first results of the Hippocates study. J Hypertension 2003; 21(1):
81-86.
185. Hibi K, Ishugami I, Tamura K, Mizushima S, Nyui N, Fujita T, Ociai H,
Kosuge M, Watanabe Y, Yoshii Y, Kihara M, Kimura K, Ishii M, Umemura
S. Endothelial nitric oxide synthase gene polymorphism and acute
myocardial infarction. Hypertension 1998; 32(3): 521 -526.
186. Hindorff LA, Heckbert SR, Tracy R, Tang Z, Psaty BM, Edwards KL,
Siscovick DS, Kronmal RA, Nazar-Stewart V. Angiotensin II type I receptor
polymorphisms in the cardiovascular health study: relation to blood
pressure, ethnicity and cardiovascular events. Am J Hypertens 2002; 15(12):
1050 – 1056.
187. Hiraga H, Oshima T, Watanabe M, Ishida M, Ishida T, Shingu T, Kambe M,
Matsuura H, Kajiyama G. Angiotensin I-converting enzyme gene
polymorphism and salt-sensitivity in essential hypertension. Hypertension.
1996; 27: 569 –572.
188. Hjermann I, Helgeland A, Holme I, Lund-Larsen PG, Leren P. The
association between blood pressure and serum cholesterol in healthy men:
the Oslo study. J Epidemiol Community Health 1978; 32(2): 117-123.
189. Hollenberg NK. Intrarenal and systemic actions of the renin-angiotensin
system. Implications for renal excretory function and sodium homeostasis.
Contrib Nephrol 1984a; 43:102 - 113.
190. Hollenberg NK. The renin-angiotensin system and sodium homeostasis. J
Cardiovasc Pharmacol 1984b; 6(Suppl 1): S176 – S183.
191. Hsueh WA and Baxter JD. Human prorenin. Hypertension. 1991; 17(4):
469–477.
192. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA,
Fishman MC. Hypertension in mice lacking the gene for endothelial nitric
oxide synthase. Nature 1995; 377(6546): 239-242.
193. Hulley SB, Rosenman RH, Bawal RD, Brand RJ. Epidemiology as a guide
to clinical decisions. The association between triglyceride and coronary
heart disease. N Engl J Med 1980; 302(25): 1383-1389.
Bibliography
244
194. Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF.
Genome scans for blood pressure and hypertension: the National Heart,
Lung, and Blood Institute Family Heart Study. Hypertension 2002; 40(1): 1-
6.
195. Hunt SC, Geleijnse JM, Wu LL, Witteman JCM, Williams RR, Grobbee
DE. Enhanced blood pressure response to mild sodium reduction in subjects
with the 235T variant of the angiotensinogen gene. Am J Hypertens. 1999;
12: 460–466.
196. Hwang JJ, Tasi CT, Yeh HM, Chiang FT, Hsu KL, Tseng CD, Liau CS,
Tseng YZ, Lai LP. The 27- bp tandem repeat polymorphism in intron 4 of
the endothelial nitric oxide synthase gene is not associated with coronary
artery disease in a hospital-based Taiwanese population. Cardiology 2002;
97(2): 67–72.
197. Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C,
Lonn E, Charbonneau F, Anderson TJ. The T-786→C mutation in
endothelial nitric oxide synthase is associated with hypertension.
Hypertension 2002; 39(4): 919 –922.
198. Hypertension Study Group Prevalence, awareness, treatment and control of
hypertension among the elderly in Bangladesh and India: a multicentre
study. Bull World Health Organ 2001, 79(6):490-500.
199. Iams SG, McMurtry JP, Wexler BC. Aldosterone, deoxycorticosterone,
corticosterone and prolactin changes during the lifespan of chronically and
spontaneously hypertensive rats. Endocrinology 1979; 104(5): 1357–1363.
200. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-
derived relaxing factor produced and released from artery and vein is nitric
oxide. Proc Natl Acad Sci USA 1987; 84(24): 9265–9269.
201. Iliadou A, Lichtenstein P, Morgenstern R, Forsberg L, Svensson R, de Faire
U, Martin NG, Pedersen NL. Repeated blood pressure measurements in a
sample of Swedish twins: heritabilities and associations with polymorphisms
in the renin-angiotensin-aldosterone system. J Hypertens 2002; 20(8): 1543-
1550.
Bibliography
245
202. Inokucki J, Okabe H, Yamauchi T, Nagamatsu A, Nonaka G, Nishioka I.
Anti-hypertensive substance in seeds of Areca catechu L. Life Sci 1986;
38(15): 1375 – 1382.
203. Intersalt: An International Study of electrolyte exertion and blood pressure,
results for 24 hour urinary sodium and potassium excretion. Intersalt
Cooperative Research Group. BMJ 1988; 297(6644): 319 - 328.
204. Iseki K, Ikemiya Y, Fukiyama K. Blood pressure and risk of end-stage renal
disease in a screened cohort. Kidney Int Suppl 1996; 55:S69–S71.
205. Ishanov A, Okamoto H, Watanabe M, Yoneya K, Nakagawa I, Kumamoto
H, Chiba S, Hata A, Kawaguchi H, Kiabatake A. Angiotensin II type I
receptor gene polymorphism in patients with cardiac hypertrophy. Jpn Heart
J 1998; 39(1): 87 – 96.
206. Ishigami T, Umemura S, Iwamoto T, Tamura K, Hibi K, Yamaguchi S,
Nyuui N, Kimura K, Miyazaki N, Ishii M. Molecular variant of
angiotensinogen gene is associated with coronary atherosclerosis.
Circulation 1995; 91(4): 951- 954.
207. Ismail M, Akhter N, Nasir M, Firesat S, Ayub Q, Khaliq S. Association
between the angiotensin-converting enzyme gene insertion/deletion
polymorphism and essential hypertension in young Pakistani patients. J
Biochem Mol Bio 2004; 37(5): 552 - 555.
208. Ito H, Hayashi I, Izumi T, Majima M. Bradykinin inhibits development of
myocardial infarction through B2 receptor signaling by increment of
regional blood flow around the ischemic lesions in rats. Br J Pharmacol
2003; 138(1): 225–233.
209. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the
angiotensin-converting enzyme gene is a risk factor for left ventricular
hypertrophy. Circulation 1994; 90(6): 2622–2628.
210. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de
Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group.
Progression of chronic kidney disease: the role of blood pressure control,
proteinuria, and angiotensin-converting enzyme inhibition: a patient-level
meta-analysis. Ann Intern Med 2003; 139(4): 244–252.
Bibliography
246
211. Jafer TH. Hypertension and kidney disease in Asia. Curr Opin Nephrol
Hypertens 2006; 15(3): 291-295.
212. Jeng JR, Harn HJ, Jeng CY, Yueh KC, Shieh SM. Angiotensin I converting
enzyme gene polymorphism in Chinese patients with hypertension. Am J
Hypertens 1997: 10(5): 558– 561.
213. Jeunemaitre X, Charru A, Chatellier G, Dumont C, Sassano P, Soubrier F,
Menard J, Corvol P. M235T variant of the human angiotensinogen gene in
unselected hypertensive patients. J Hypertens Suppl 1993; 11(5):S80-S81.
214. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma
AM, Gimenez-Roqueplo AP, Hata A, Corvol P, Lalouel JM. Haplotypes of
angiotensinogen in essential hypertension. Am J Hum Genet 1997; 60(6):
1448 –1460.
215. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel JM. Absence of
linkage between the angiotensin converting enzyme locus and human
essential hypertension. Nat Genet 1992a; 1(1): 72–75.
216. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS,
Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P.
Molecular basis of human hypertension: Role of angiotensinogen. Cell
1992b; 71(1): 169-180.
217. Jiang Z, Zhao W, Yu F, Xu G. Association of Angiotensin II type I receptor
gene polymorphism with essential hypertension. Chin Med J 2001; 114(12):
1249-1251.
218. Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness,
treatment, control and risk factors of hypertension in Republic of Korea: the
Ansan study. J Hypertens 2001; 19 (9): 1523–1532.
219. Johanning GL, Johnston KE, Tamura T, Goldenberg RL. Ethnic differences
in angiotensin converting enzyme gene polymorphism. J Hypertens 1995;
13(6): 710–711.
220. Jorgensen RS and Houston BK. Family history of hypertension, personality
patterns, and cardiovascular reactivity to stress. Psychosom Med 1986; 48(1-
2): 102-107.
Bibliography
247
221. Joseph A, Kutty VR, Soman CR. High risk for coronary heart disease in
Thiruvananthapuram city: a study of serum lipids and other risk factors.
Indian Heart J 2000; 52(1): 29–35.
222. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The
association of borderline hypertension with target organ changes and higher
coronary risk. Tecumseh Blood Pressure study. JAMA 1990; 264(3): 354-
358.
223. Kahn EB, Ramsey LT, Brownson RC, Heath GW, Howze EH, Powell KE,
Stone EJ, Rajab MW, Corso P. The effectiveness of interventions to increase
physical activity: A systematic review. Am J Prev Med 2002; 22(4): 73 –
107.
224. Kainulainen K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvanen
AC, Vartianen E, Peltonen L, Kontula K. Evidence for involvement of the
type 1 angiotensin II receptor locus in essential hypertension. Hypertension
1999; 33(3): 844-849.
225. Kajiyama N, Saito Y, Miyamoto Y, Yoshimura M, Nakayama M, Harada M,
Kuwahara K, Kishimoto I, Yasue H, Nakao K. Lack of association between
T-786→C mutation in the 5’-flanking region of the endothelial nitric oxide
synthase gene and essential hypertension. Hypertens Res 2000; 23(6): 561–
565.
226. Kalavathy MC, Thankappan KR, Sarma PS, Vasan RS. Prevalence,
awareness, treatment and control of hypertension in an elderly community-
based sample in Kerala, India. Natl Med J India 2000; 13(1): 9 – 15.
227. Kamdar S, Daniel H, Fogarty P, Lawson M, Munroe P, Caulfield M. ACE
insertion/deletion (I/D) polymorphism in Vincentian African Caribbean with
essential hypertension. J Hum Hypertens 1994; 8(8): 611.
228. Kario K, Hoshide S, Umeda Y, Sato Y, Ikeda U, Nishiuma S, Matsuo M,
Shimada K. Angiotensinogen and angiotensin-converting enzyme
genotypes, and day and night blood pressures in elderly Japanese
hypertensives. Hypertens Res 1999; 22(2): 95–103.
229. Kario K, Matsuo T, Kobayashi H, Kanai N, Hoshide S, Mitsuhashi T, Ikeda
U, Nishiuma S, Matso M, Shimada K. Endothelial cell damage and
Bibliography
248
angiotensin-converting enzyme insertion/deletion genotype in elderly
hypertensive patients. J Am Coll Cardiol 1998; 32(2): 444–450.
230. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, Yazaki
Y. Lack of evidence for association between the endothelial nitric oxide
synthase gene and hypertension. Hypertension 1999; 33(4): 933-936.
231. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J.
Global burden of hypertension: analysis of worldwide data. Lancet 2005;
365(9455): 217-223.
232. Keys A, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS,
Fidanza F, Karvonen MJ, Kimura N, Menotti A, Mohacek I, Nedeljkovic S,
Puddu V, Punsar S, Taylor HL, van Buchem FSP. Seven Countries: A
multivariate analysis of death and coronary heart disease. London: Harvard
University Press; 1980.
233. Khoury S, Yarows SA, O’Brien TK, Sowers JR. Ambulatory blood pressure
monitoring in a nonacademic setting. Effects of age and sex. Am J
Hypertens 1992; 5(9): 616 – 623.
234. Kihara M, Umemura S, Kadota T, Yabana M, Tamura K, Nyui N, Ogawa N,
Murakami K, Fukamizu A, Ishii M. The neuronal isoform of constitutive
nitric oxide synthase is up-regulated in the macula densa of angiotensinogen
gene-knockout mice. Lab Invest 1997; 76(2): 285–294.
235. Kikuya M, Sugimoto K, Katsuya T, Suzuki M, Sato T, Funahashi J, Katoh
R, Kazama I, Michimata M, Araki T, Hozawa A, Tsuji I, Ogihara T,
Yanagisawa T, Imai Y and Matsubara M. A/C1166 gene polymorphism of
the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: the
Ohasama Study. Hypertens Res 2003; 26(2): 141-145.
236. Kim JU, Chang HK, Lee SS, Kim JW, Kim KT, Lee SW, Chung WT.
Endothelial nitric oxide synthase gene polyrnorphisms in Behcet’s disease
and rheumatic diseases with vasculitis. Ann Rheum Dis 2003; 62(11): 1083-
1087.
237. Kimura G and Brenner BM. Implications of linear pressure-natriuresis
relationship and importance of sodium sensitivity in hypertension. J
Hypertens 1997; 15(10): 1055-1061.
Bibliography
249
238. Kimura S, Mullins JJ, Bunnemann B, Metzger R, Hilgenfeldt U,
Zimmermann F, Jacob H, Fuxe K, Ganten D, Kaling M. High blood pressure
in transgenic mice carrying the rat angiotensinogen gene. EMBO Journal
1992; 11(3):821 – 827.
239. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS,
Karmpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson
CM; TIMI Study Group. Serum blood urea nitrogen as an independent
marker of subsequent mortality among patients with acute coronary
syndromes and normal to mildly reduced glomerular filtration rates. J Am
Coll Cardiol 2005; 45(11): 1781-1786.
240. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE,
Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men.
N Engl J Med 1996; 334(1): 13–18.
241. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously
treating dyslipidemias and hypertension? Atherosclerosis 2008; 196(1): 1-8.
242. Kokkinos PF, Holland JC, Pittaras AE, Narayan P, Dotson CO,
Papademetriou V. Cardiorespiratory fitness and coronary heart disease risk
factor association in women. J Am Coll Cardiol. 1995; 26(2): 358 - 364.
243. Komiya I, Yamada T, Takasu N, Asawa T, Akamine H, Yagi N, Nagasawa
Y, Ohtsuka H, Miyahara Y, Sakai H, Sato A, Aizawa T. An abnormal
sodium metabolism in Japanese patients with essential hypertension, judged
by serum sodium distribution, renal function and the renin-aldosterone
system. J Hypertens 1997; 15(1): 65–72.
244. Kramer-Guth A, Quaschning T, Greiber S, Wanner C. Potential role of
lipids in the progression of diabetic nephropathy. Clin Nephrol 1996; 46(4):
262- 265.
245. Krege JH, Kim HS, Moyer JS, Jennette JC, Peng L, Hiller SK, Smithies O.
Angiotensin-converting enzyme gene mutations, blood pressures, and
cardiovascular homeostasis. Hypertension 1997; 29(1): 150 –157.
246. Krieger JE and Dzau VJ. Molecular biology of hypertension. Hypertension
1991; 18(suppl 3): I3-I17.
Bibliography
250
247. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of
leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88(11): 4651– 4655.
248. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH.
A novel mechanism for the beneficial vascular effects of high-density
lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial
nitric oxide synthase expression. Am Heart J 2002; 144(1): 165-172.
249. Laaksonen DE, Niskanen L, Nyyssonen K, Lakka TA, Laukkanen JA,
Salonen JT. Dyslipidaemia as a predictor of hypertension in middle-aged
men. Eur Heart J 2008; 29(20): 2561-2568.
250. Lacolley P, Gautier S, Poirier O, Pannier B, Cambien F, Benetos A. Nitric
oxide synthase gene polymorphisms, blood pressure and aortic stiffness in
normotensive and hypertensive subjects. J Hypertens 1998; 16(1): 31-35.
251. Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, Cambien F,
Benetos A. Angiotensin II type 1 receptor-153A/G and 1166A/C gene
polymorphisms and increase in aortic stiffness with age in hypertensive
subjects. J Hypertension 2001; 19(3): 407-413.
252. Lane DA and Lip GY. Ethnic differences in hypertension and blood pressure
control in the UK. QJM 2001; 94(7): 391-396.
253. Laurenzi M, Mancini M, Menotti A, Stamler J, Stamler R, Trevisan M,
Zanchetti A. Multiple risk factors in hypertension: results from the Gubbio
study. J Hypertens 1990; 8(1):S7-S12.
254. Lawes CM, Vander Hoorn S, Rodgers A; International Society of
Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet
2008; 371(9623): 1513-1518.
255. Ledingham JM. Distribution of water, sodium and potassium in heart and
skeletal muscle in experimental renal hypertension in rats. Clin Sci 1953;
12(4): 337 - 349.
256. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular filtration rate from serum creatinine:
a new prediction equation. Modification of diet in Renal Disease Study
Group. Ann Intern Med 1999; 130(6): 461-470.
Bibliography
251
257. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E,
Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective
effect of the angiotensin-receptor antagonist irbesartan in patients with
nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–860.
258. Li R, Lyn D, Lapu-Bula R, Oduwole A, Igho-Pemu P, Lankford B, Morgan
J, Nkemdechi S, Liu G, Pack C, Silvestrov N, von-Deutsch DA, Song Q,
Abukhalaf IK, Ofili E. Relation of endothelial nitric oxide synthase gene to
plasma nitric oxide level, endothelial function, and blood pressure in African
Americans. Am J Hypertens 2004; 17(7): 560- 567.
259. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human
hypertension. Cell 2001; 104(4): 545–556.
260. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release
of endothelium-derived relaxing factor in human forearm circulation in vivo.
Blunted response in essential hypertension. Circulation 1990; 81(6): 1762 -
1767.
261. Lindpainter K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, La Motte
F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin-
converting-enzyme gene polymorphism and the risk of ischemic heart
disease. N Engl J Med 1995; 332(11): 706–711.
262. Low PS, Saha N, Tay TS. Ethnic variation of cord plasma apolipoprotein
levels in relation to coronary risk level: a study in three ethnic groups of
Singapore. Acta Paeditr 1996; 85(12): 1476-1482.
263. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel JM, Ward RH.
Angiotensin-converting enzyme gene polymorphism is associated with
myocardial infarction but not with development of coronary stenosis.
Circulation 1995; 91(8): 2120-2124.
264. Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA,
Weinberger MH. Salt sensitivity and resistance of blood pressure. Age and
race as factors in physiological responses. Hypertension 1991; 17(suppl1):
102-108.
Bibliography
252
265. Luscher TF. Functional abnormalities of the vascular endothelium in
hypertension and atherosclerosis. Scand J Clin Lab Invest Suppl 1990; 199:
28-32.
266. MacMahon SW, Macdonald GJ, Blacket RB. Plasma lipoprotein levels in
treated and untreated hypertensive men and women. The National Heart
Foundation of Australia Risk Factor Prevalence Study. Arteriosclerosis
1985; 5(4): 391-396.
267. Mahanta TG, Ahmed FU, Mahanta BN, Barua A. Prevalence of
Hypertension and its risk factors in a Tea Garden Community of Dibrugarh
District, Assam. Indian J Public Health 2008; 52(1): 45-47.
268. Malhotra P, Kumari S, Kumar R, Jain S, Sharma BK. Prevalence and
determinants of hypertension in an un-industrialised rural population of
North India. J Hum Hypertens 1999; 13(7): 467 – 472.
269. Malik R, Pirzado ZA, Ahmed S, Sajid M. Study of lipid profile, blood
pressure and blood glucose in rural population. Pak J Med Res 1995; 34:
152-155.
270. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano
G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope
L, Rynkiewicz A, Schmieder RE, Boudier HA,Zanchetti A, Vahanian
A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-
Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber
S, Tendera M, Widimsky P,Zamorano JL, Erdine S, Kiowski W, Agabiti-
Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos
S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine
S, Farsang C, Gaita D,Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien
E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber
B, Williams B; Management of Arterial Hypertension of the European
Society of Hypertension; European Society of Cardiology. 2007 Guidelines
for the management of Arterial Hypertension. The task force for the
management of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology (ESC). J
Hypertens 2007; 25(6): 1105-1187.
Bibliography
253
271. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the
value of prospective cohort studies. Nat Rev Genet 2006; 7(10): 812– 820.
272. Manuck SB, Kaplan JR, Adams MR, Clarkson TB. Effects of stress and the
sympathetic nervous system on coronary atherosclerosis in the cynomolgus
macaque. Am Heart J 1988; 116(1): 328-333.
273. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC,
Correa RX, Rios-Santos F, Tanus-Santos JE. Consistent interethnic
differences in the distribution of clinically relevant endothelial nitric oxide
synthase genetic polymorphisms. Nitric Oxide 2005; 12(3): 177–182.
274. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui
LC, Schappert KT. Structure and chromosomal localization of the human
constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;
268(23): 17478-17488.
275. Martinez E, Puras A, Escribano J, Sanchis C, Carrion L, Artigao M, Divison
JA, Masso J, Vidal A, Fernandez JA. Angiotensin-converting enzyme
(ACE) gene polymorphisms, serum ACE activity and blood pressure in a
Spanish-Mediterranean population. J Hum Hypertens 2000; 14(2): 131–135.
276. Masubuchi Y, Kumai T, Uematsu A, Komoriyama K, Hirai M.
Gonadectomy-induced reduction in blood pressure in adult spontaneously
hypertensive rats. Acta Endocrinol (Copenh) 1982; 101(1): 154 –160.
277. Mathur KS and Sapru RP. The aetiology and incidence of heart disease - a
changing pattern over the fifteen year period 1947 to 1961. J Assoc
Physicians India 1963; 11: 651-659.
278. Matyar S, Attila G, Acarturk E, Akpinar O, Inal T. eNOS gene intron4 a/b
VNTR polymorphism is a risk factor for coronary artery disease in Southern
Turkey. Clin Chim Acta 2005; 354(1 – 2): 153-158.
279. Mayhan WG and Sharpe GM. Superoxide dismutase restores endothelium-
dependent arteriolar dilatation during acute infusion of nicotine. J Appl
Physiol 1998; 85(4): 1292–1298.
280. McGill HC Jr and Strong JP. The geographic pathology of atherosclerosis.
Ann N Y Acad Sci 1968; 149(2): 923 - 927.
Bibliography
254
281. Melander O, von Wowern F, Frandsen E, Burri P, Willsteen G, Aurell M,
Hulthen UL. Moderate salt restriction effectively lowers blood pressure and
degree of salt sensitivity is related to baseline concentration of renin and N-
terminal atrial natriuretic peptide in plasma. J Hypertens 2007; 25(3): 619-
627.
282. Menard J, Clauser E, Bouhnik J, Corvol P. Angiotensinogen biochemistry.
In: Robertson JIS and Nicholls MG (eds). The Renin-Angiotensin System.
London, UK: Gower Mediacl Pub; 1993: 8.1– 8.10.
283. Menard J, el Amrani AI, Savoie F, Bouhnik J. Angiotensinogen: an
attractive but underrated participant in hypertension and inflammation.
Hypertension 1991; 18(5): 705-707.
284. Meneely GR and Dahl LK. Electrolytes in hypertension: the effects of
sodium chloride. The evidence from animal and human studies.
Hypertension and its treatment. Med Clin North Am 1961; 45: 271 - 283.
285. Mikkelsen KL, Wiinberg N, Hoegholm A, Christensen HR, Bang LE,
Nielsen PE, Svendsen TL, Kampmann JP, Madsen NH, Bentzon MW.
Smoking related to 24-h ambulatory blood pressure and heart rate: a study in
352 normotensive Danish subjects. Am J Hypertens 1997; 10(5): 483- 491.
286. Milan A, Mulatero P, Rabbia F, Veglio F. Salt intake and hypertension
therapy. J Nephrol 2002; 15 (1): 1-6.
287. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama
M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka
I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa
Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, Nakao K. Endothelial nitric
oxide synthase gene is positively associated with essential hypertension.
Hypertension 1998; 32(1): 3– 8.
288. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T,
Yoshimura M, Harada M, Kajiyama N, Kishimoto I, Kuwahara K, Hino J,
Ogawa E, Hamanaka I, Kamitani S, Takahashi N, Kawakami R, Kangawa
K, Yasue H, Nakao K. Replication protein A1 reduces transcription of the
endothelial nitric oxide synthase gene containing a -786T→C mutation
Bibliography
255
associated with coronary spastic angina. Hum Mol Genet 2000; 9(18):
2629–2637.
289. Moe KT, Lim ST, Wong P, Chua T, DeSilva DA, Koh TH, Wong MC, Chin
– Dusting J. Association of endothelial nitric oxide synthase gene
polymorphism with primary hypertension in a Singapore population. J Hum
Hypertens 2006; 20(12): 956-963.
290. Moeslinger T, Friedl R, Volf I, Brunner M, Baran H, Koller E,
Spieckermann P. Urea induces macrophage proliferation by inhibition of
inducible nitric oxide synthesis. Kidney Int 1999; 56(2): 581-588.
291. Mohan V, Deepa M, Farooq S, Datta M, Deepa R. Prevalence, awareness
and control of hypertension in Chennai – The Chennai Urban Rural
Epidemiology Study (CURES-52). J Assoc Physicians India 2007; 55: 326-
332.
292. Mohan V, Deepa R, Rani SS, Premalatha G; Chennai Urban Population
Study (CUPS No. 5). Prevalence of coronary artery disease and its
relationship to lipids in a selected population in South India: The Chennai
Urban Population Study (CUPS No. 5). J Am Coll Cardiol 2001; 38(3):
682–687.
293. Molavi B and Mehta JL. Oxidative stress in cardiovascular disease:
molecular basis of its deleterious effects, its detection and therapeutic
considerations. Curr Opin Cardiol 2004; 19(5): 488 – 493.
294. Moncada S and Higgs A. The L-arginine-nitric oxide pathway. New Engl J
Med 1993; 329(27): 2002–2012.
295. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109 –142.
296. Moncada S. The L-arginine-nitric oxide pathway. Acta Physiol Scand 1992;
145(3): 201–227.
297. Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson P,
Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL,
Brynes AE, Saeed N, Barnard N, Bell M, Bell JD, Prasad K, Rayson M,
Talmud PJ, Humphries SE. Human gene for physical performance. Nature
1998; 393(6682): 221–222.
Bibliography
256
298. Morgan T, Carney S, Wilson M. Interrelationship in humans between
sodium intake and hypertension. Clin Exp Pharmacol Physiol 1975; (Suppl
2): 127 - 129.
299. Morgan T, Craven C, Nelson L, Lalouel JM, Ward K. Angiotensinogen
T235 expression is elevated in decidual spiral arteries. J Clin Invest 1997;
100(6): 1406–1415.
300. Morise T, Takeuchi Y, Takeda R. Angiotensin-converting enzyme
polymorphism and essential hypertension. Lancet 1994; 343(8889): 125.
301. Morise T, Takeuchi Y, Takeda R. Rapid detection and prevalence of the
variants of the angiotensinogen gene in patients with essential hypertension.
J Intern Med 1995; 237(2): 175–180.
302. Mufunda J, Scott LJ, Chifamba J, Matenga J, Sparks B, Cooper R, Sparks H.
Correlates of blood pressure in an urban Zimbabwean population and
comparison to other populations of African origin. J Hum Hypertens 2000;
14(1): 65–73.
303. Muntzel M and Drueke T. A comprehensive review of the salt and blood
pressure relationship. Am J Hypertens 1992; 5(4): 1S - 42S.
304. Murphy RJ. The effect of "rice diet" on plasma volume and extracellular
fluid space in hypertensive subjects. J Clin Invest 1950; 29(7): 912 - 917.
305. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE.
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor.
Nature 1991; 351(6323):233- 236.
306. Murray CJ and Lopez AD. Mortality by cause for eight regions of the world:
Global Burden of Disease Study. Lancet 1997; 349(9061): 1269–1276.
307. Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F. Gene structure,
polymorphism and mapping of the human endothelial nitric oxide synthase
gene. Biochem Biophys Res Commun 1994; 198(3): 1027-1033.
308. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itho T, Miyakawa T, Iwasaki
R, Hiramori K. Deletion polymorphism of the angiotensin I-converting
enzyme gene is associated with serum ACE concentration and increased risk
for CAD in the Japanese. Circulation 1994; 90(5): 2199-2202.
Bibliography
257
309. Nakaki T, Hishikawa K, Suzuki H Saruta T, Kato R. L-Arginine induced
hypotension. Lancet 1990; 336(8716): 696.
310. Nakano Y, Oshima T, Hiraga H, Matsuura H, Kajiyama G, Kambe M. DD
genotype of angiotensin I-converting enzyme gene is a risk factor for early
onset of essential hypertension in Japanese patients. J Lab Clin Med 1998;
131(6): 502-506.
311. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa
H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K. T-786→C
mutation in the 5′-flanking region of the endothelial nitric oxide synthase
gene is associated with coronary spasm. Circulation 1999; 99(22): 2864–
2870.
312. Nasreen S, Nabika T, Shibata H, H Moriyama, K Yamashita, J Masuda, S
Kobayashi S. T-786C polymorphism in endothelial NO synthase gene
affects cerebral circulation in smokers: possible gene-environmental
interaction. Arterioscler Thromb Vasc Biol 2002; 22(4): 605-610.
313. Nishevitha NS, Angeline T, Jeyaraj N. Endothelial nitric oxide synthase
(eNOS) Glu298→Asp polymorphism (G894T) among south Indians. Indian
J Med Res 2009; 129: 68-71.
314. Nishiuma S, Kario K, Kayaba K, Nagio N, Shimada K, Matsuo T, Matsuo
M. Effect of the angiotensinogen gene Met235→Thr variant on blood
pressure and other cardiovascular risk factors in two Japanese populations. J
Hypertens 1995; 13(7): 717- 722.
315. Niu T, Xu X, Rogus J, Zhou Y, Chen C, Yang J, Fang Z, Schmitz C, Zhao
J, Rao VS, Lindpaintner K. Angiotensinogen Gene and Hypertension in
Chinese. J Clin Invest 1998; 101(1): 188–194.
316. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A.
HDL and arteriosclerosis: beyond reverse cholesterol transport.
Atherosclerosis 2002; 161(1): 1-16.
317. Obrist PA. The cardiovascular behavioural - interaction as it appears today.
Psychophysiology 1976; 13(2): 95-107.
Bibliography
258
318. Oghagbon EK and Okesina AB. Pattern of some risk factors for
cardiovascular disease in untreated Nigerian hypertensive patients. West Afr
J Med 2006; 25(3): 190-194.
319. Ogunkeye OO and Ighogboja IS. Increase in total serum triglyceride and
phospholipids in kwashiorkor. Ann Trop Pediatr 1992; 12(4): 463-466.
320. Ohkubo H, Kawakami H, Kakehi Y,Takumi T, Arai H, Yokota Y, Iwai M,
Tanabe Y, Masu M, Hata J, Iwao H, Okamoto H, Yokoyama M, Nomura T,
Katsuki M, Nakanishi S. Generation of transgenic mice with elevated blood
pressure by introduction of the rat renin and angiotensinogen genes. Proc
Natl Acad Sci (USA) 1990; 87(13): 5153-5157.
321. Olatunbosun ST, Kaufman JS, Cooper RS, Bella AF. Hypertension in a
black population: prevalence and biosocial determinants of high blood
pressure in a group of urban Nigerians. J Hum Hypertens 2000; 14(4): 249-
257.
322. Omogbai EK, Ozolua RI, Ebeigbe AB. Effects of potassium adaptation on
blood pressure and pressor responses in normotensive and renal
hypertensive wistar rats. Methods Find Exp Clin Pharmacol 2005; 27(1): 5-
10.
323. Ono K, Mannami T, Baba S, Yasui N, Ogihara T, Iwai N. Lack of
association between angiotensin II type I receptor gene polymorphism and
hypertension in Japanese Hypertens Res 2003; 26(2): 131-134.
324. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann
Intern Med 2003; 139(9): 761-776.
325. Osman OB, El-tahtawy MY, Soliman HA. Serum lipoprotein cholesterol in
hypertensive patients. J Egyptian Med Ass 1987; 5: 437- 455.
326. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp
MA, Danser AH. AT1 receptor A/C1166 polymorphism contributes to
cardiac hypertrophy in subjects with hypertrophic cardiomyopathy.
Hypertension 1998; 32(5): 825-830.
327. Ostfeld R, Mookherjee D, Spinelli M, Holtzman D, Shoyeb A, Schaefer M,
Doddamani S, Spevack D, Du Y. A triglyceride/high-density lipoprotein
Bibliography
259
ratio > or = 3.5 is associated with an increased burden of coronary artery
disease on cardiac catheterization. J Cardiometab Syndr 2006; 1(1): 13-15.
328. Ouchi Y, Share L, Crofton JT, Iitake K, Brooks DP. Sex difference in the
development of deoxycorticosterone-salt hypertension in the rat.
Hypertension. 1987; 9(2): 172–177.
329. Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S,
Ardaillou R, Soubrier R. Genotype-phenotype relationships for the renin-
angiotensin- aldosterone system in a normal population. Hypertension 1999;
34(3): 423-429.
330. Pais P, Fay MP, Yusuf S. Increased risk of acute myocardial infarction
associated with beedi and cigarette smoking in Indians: final report on
tobacco risks from a case-control study. Indian Heart J 2001; 53(6): 731-
735.
331. Palatini P, Graniero GR, Mormino P, Nicolosi L, Mos L, Visentin P, Pessina
AC. Relation between physical training and ambulatory blood pressure in
stage I hypertensive subjects. Results of the HARVEST Trial. Hypertension
and Ambulatory Recording Venetia Study. Circulation 1994; 90(6): 2870 -
2876.
332. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize
nitric oxide from L-arginine. Nature 1988; 333(6174): 664-666.
333. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the
biological activity of endothelium derived relaxing factor. Nature 1987;
327(6122): 524-526.
334. Pan WH, Tseng WP, You FJ, Tai Y, Chou J. Positive relationship between
urinary sodium chloride and blood pressure in Chinese health examinees and
its association with calcium excretion. J Hypertens 1990; 8(9): 873 - 878.
335. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-
dependent vascular relaxation in patients with essential hypertension. N Engl
J Med 1990; 323(1): 22 - 27.
336. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide
synthases in the cardiovascular system. Cardiovasc Res 1999; 43 (3): 509–
520.
Bibliography
260
337. Pasha MAQ, Khan AP, Kumar R, Grover SK, Ram RB, Norboo T,
Srivastava KK, Selvamurthy W, Brahmachari SK. Angiotensin converting
enzyme insertion allele in relation to high altitude adaptation. Ann Hum
Genet 2001; 65(6): 531–536.
338. Pasha MAQ, Khan AP, Kumar R, Ram RB, Grover SK, Srivastava KK,
Selvamurthy W, Brahmachari SK. Variation in angiotensin converting
enzyme gene insertion/deletion polymorphism in Indian population of
different ethnic origins. J Biosci 2002; 27(1): 67-70.
339. Patkar S, Charita BH, Ramesh C, Padma T. High risk of essential
hypertension in males with intron 4 VNTR polymorphism of eNOS gene.
Indian J Hum Genet 2009; 15(2): 49-53.
340. Paxton WC, Runge M, Horaist C, Horulst C, Cohen C, Alexander RW,
Bernstein KE. Imunohistochemical localization of rat angiotensin II AT 1
receptor. Am J Physiol 1993; 264(6): 989 - 995.
341. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of
action. Physiol Rev 1977; 57(2): 313–370.
342. Pelkonen R, Nikkila EA, Koskinen S, Penttinen K, Sarna S. Association of
serum lipids and obesity with cardiovascular mortality. Br Med J 1977;
2(6096): 1185-1187.
343. Pereira AC, Mota GF, Cunha RS, Herbenhoff FL, Mill JG, Krieger JE.
Angiotensinogen 235T allele “dosage” is associated with blood pressure
phenotypes. Hypertension 2003; 41(1): 25-30.
344. Perloff D, Grim C, Flack J, Frohloch ED, Hill M, McDonald M,
Morgenstern BZ. Human blood pressure determination by
sphygmomanometry. Circulation 1993; 88(5): 2460-2470.
345. Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A
prospective study of blood pressure and serum creatinine. Results from the
’Clue’ Study and the ARIC Study. JAMA. 1993; 269(4): 488–493.
346. Perola M, Kainulainen K, Pajukanta P, Terwilliger JD, Hiekkalinna T,
Ellonen P, Kaprio J, Koskenvuo M, Kontula K, Peltonen L. Genome-wide
scan of predisposing loci for increased diastolic blood pressure in Finnish
siblings. J Hypertens 2000; 18(11): 1579- 1585.
Bibliography
261
347. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G,
Moskowitz DW, Carmody SE. Early predictors of 15-year end-stage renal
disease in hypertensive patients. Hypertension 1995; 25(4): 587–594.
348. Perticone F, Ceravolo R, Maio R, Ventura G, Zingone A, Perrotti N,
Mattioli PL. Angiotensin-converting enzyme gene polymorphism is
associated with endothelium-dependent vasodilation in never treated
hypertensive patients. Hypertension 1998; 31(4): 900–905.
349. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG,
King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control,
proteinuria, and the progression of renal disease. The Modification of Diet in
Renal Disease Study. Ann Intern Med 1995; 123(10): 754–762.
350. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones
DW, Kurtz T, Sheps SG, Rocella EJ. Recommendations for blood pressure
measurement in Humans and Experimental animals: Part1: Blood pressure
measurement in humans: A statement for professionals from the
subcommittee of professional and public education of the American Heart
Association Council on High Blood Pressure Research. Hypertension 2005;
45: 142-161.
351. Pickering TG. The effects of environmental and lifestyle factors on blood
pressure and the intermediary role of the sympathetic nervous system. J
Hum Hypertens 1997; 11(suppl 1): S9-S18.
352. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de la Sierra A. Molecular
Basis of Salt Sensitivity in Human Hypertension: Evaluation of Renin-
Angiotensin-Aldosterone System Gene Polymorphisms. Hypertension 2001;
38(5): 1204 – 1209.
353. Pocock SJ, Shaper AG, Phillips AN. Concentrations of high density
lipoprotein cholesterol, triglycerides and total cholesterol in ischaemic heart
disease. BMJ 1989; 298(6679): 998-1002.
354. Poirier P, Catellier C, Tremblay A, Nadeau A. Role of body fat loss in the
exercise-induced improvement of the plasma lipid profile in noninsulin
dependent diabetes mellitus. Metabolism 1996; 45(11): 1383-1387.
Bibliography
262
355. Pontremoli R, Ravera M, Viazzi F, Nicolella C, Berruti V, Leoncini G,
Giacopelli F, Bezante G P, Sacchi G, Ravazzolo R, Deferrari G. Genetic
polymorphism of the renin– angiotensin system and organ damage in
essential hypertension. Kidney Int 2000; 57(2): 561–569.
356. Poulsen PL, Ebbehoj E, Hassen KW, Mogensen CE. Effects of smoking on
24-h ambulatory blood pressure and autonomic function in normalbuminuric
insulin dependent diabetes mellitus patients. Am J Hypertens 1998; 11(9):
1093–1099.
357. Procopciuc L, Popescu T, Jebeleanu G, Pop D, Zdrenghea D. Essential
arterial hypertension and polymorphism of angiotensinogen M235T gene. J
Cell Mol Med 2002; 6(2): 245-250.
358. Procopciuc LM, Pop D, Zdrenghea D, Jebeleanu G. Genetic analysis of
angiotensinogen gene polymorphisms (M235T and T174M) in Romanian
patients with essential arterial hypertension. Rom J Intern Med 2005; 43(1-
2): 61-71.
359. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM,
Panza JA, Cannon RO 3rd
. Nitric oxide activity in the human coronary
circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest
1995; 95(4): 1747–1755.
360. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced
membrane lipid peroxidation: the cytotoxic potential of superoxide and
nitric oxide. Arch Biochem Biophys 1991; 288(2): 481–487.
361. Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine:
nitric oxide pathway in human platelets. Br J Pharmacol 1990; 101(2): 325 –
328.
362. Randall OS, Westerhoff N, van den Bos GC, Alexander B. Reliability of
stroke volume to pulse pressure ratio for estimating and detecting changes in
arterial compliance. J Hypertens Suppl 1986; 4(5): S293– S296.
363. Rathaus M and Bernheim J. Oxygen species in the microvascular
environment: regulation of vascular tone and the development of
hypertension. Nephrol Dial Transplant 2002; 17(2): 216–221.
Bibliography
263
364. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowers BD, Zisman
LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype
in patients with ischemic or idiopathic cardiomyopathy. Lancet 1993;
342(8879): 1073-1075.
365. Reaven GM and Hoffman BB. Hypertension as a disease of carbohydrate
and lipoprotein metabolism. Am J Med 1989; 87(6A): 2S-6S.
366. Reaven PD, Barrett-Connor E, Edelstein S. Relation between leisure-time
physical activity and blood pressure in older women. Circulation 1991;
83(2): 559 - 565.
367. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in
patients with type 2 diabetes. N Engl J Med 2002; 346(15):1145-1151.
368. Ribeiro MO, Antunes E, de-Nucci G, Lovisolo SM, Zatz R. Chronic
inhibition of nitric oxide synthase. A new model of arterial hypertension.
Hypertension 1992; 20(3): 298-303.
369. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the
human angiotensin converting enzyme. Nat Genet 1999; 22(1): 59–62.
370. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting enzyme
gene accounting for half the variance of serum enzyme levels. J Clin Invest
1990; 86(4): 1343-1346.
371. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/
deletion polymorphism of the human angiotensin converting enzyme gene
(DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20(6):
1433.
372. Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood
pressure related cardiovascular disease. J Hypertens Suppl 2000; 18(1): S3–
S6.
373. Rose AM, Grais RF, Coulombier D, Ritter H. A comparison of cluster and
systematic sampling methods for measuring crude mortality. Bull World
Health Organ 2006; 84(4): 290-296.
Bibliography
264
374. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal
insufficiency in treated essential hypertension. N Engl J Med 1989; 320(11):
684–688.
375. Rotimi C, Morrison L, Cooper R, Oyejide C, Effiong E, Ladipo M,
Osotemihen B, Ward R. Angiotensinogen gene in human hypertension. Lack
of an association of the 235T allele among African Americans. Hypertension
1994, 24(5): 591-594.
376. Rowland NE and Fregly MJ. Role of gonadal hormones in hypertension in
the Dahl salt-sensitive rat. Clin Exp Hypertens A 1992; 14(3): 367–375.
377. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on
the pathogenesis of cardiovascular disease and implications for therapy.
Circulation 1990; 99(16): 2192-2217.
378. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage
renal disease: when to start and why possibly never to stop: a post hoc
analysis of the REIN trial results: Ramipril Efficacy in Nephropathy. J Am
Soc Nephrol 2001; 12(12): 2832–2837.
379. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG,
Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. the
effect of pravastatin on coronary events after myocardial infarction in
patients with average cholesterol levels. Cholesterol and Recurrent Events
Trial Inestigators. N Engl J Med 1996; 335(14): 1001 – 1009.
380. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D,
Obarzanek E, Conlin PR, Miller ER 3rd
, Simons-Morton DG, Karanja N,
Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood
pressure of reduced sodium and the Dietary Approaches to Stop
Hypertension (DASH) diet. N Engl J Med 2001; 344(1): 3-10.
381. Sagnella GA, Rothwell MJ, Onipinla AK, Wicks PD, Cook PG, Cappuccio
FP. A population study of ethnic variations in the angiotensin-converting
enzyme I/D polymorphism: relationships with gender, hypertension and
impaired glucose metabolism. J Hypertens 1999; 17(5): 657–664.
382. Salonen JT, Puska P, Kottke TE, Heinonen OP. Coronary risk factor
clustering patterns in eastern Finland. Int J Epidemiol 1981; 10(3): 203-210.
Bibliography
265
383. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos
JE. Susceptible and protective eNOS haplotypes in hypertensive black and
white subjects. Atherosclerosis 2006; 186(2): 428–432.
384. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C,
Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in
apparently healthy men. J Am Soc Nephrol 2003; 14(8): 2084 - 2091.
385. Schmidt HH and Walter U. NO at work. Cell 1994; 78(6): 919-925.
386. Schmidt S, Beige J, Walla-Friedel M, Michel MC, Sharma AM, Ritz E. A
polymorphism in the gene for the angiotensin II type 1 receptor is not
associated with hypertension. J Hypertens 1997; 15(12): 1385–1388.
387. Schmidt S, van Hooft IM, Grobbe DE, Ganten D, Ritze E. Polymorphism of
angiotensin I converting enzyme gene is apparently not related to high blood
pressure: Dutch Hypertension and Offspring Study. J Hypertens 1993;
11(4): 345-348.
388. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM. Angiotensinogen
M235T variant and salt sensitivity in young normotensive Caucasians. J
Hypertens 1999; 17: 475– 479.
389. Schunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, Lorell BH,
Riegger GA. Association between a deletion polymorphism of the
angiotensin converting- enzyme gene and left ventricular hypertrophy. N
Engl J Med 1994; 330(23): 1634-1638.
390. Schunkert H, Hense HW, Muscholl M, Luchner A, Kurzinger S, Danser AH,
Riegger GA. Associations between circulating components of the renin-
angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77(1):
24-31.
391. Schut AF, Sayed-Tabatabaei FA, Witteman JC, Avella AM, Vergeer JM,
Pols HA, Hofman A, Deinum J, vanDuijn CM. Smoking-dependent effects
of the angiotensin-converting enzyme gene insertion/deletion polymorphism
on blood pressure. J Hypertens 2004; 22(2): 313–319.
392. Serrano NC, Paez C, Correa PA, Anaya JM. Endothelial nitric oxide
synthase gene polymorphism is associated with systemic lupus
erythematosus. J Rheumatol 2004; 31(11): 2163 – 2168.
Bibliography
266
393. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in
dogs increases coronary vascular nitric oxide production and endothelial cell
nitric oxide synthase gene expression. Circ Res 1994; 74(2): 349-353.
394. Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM. A prospective
study of plasma lipid levels and hypertension in women. Arch Intern Med
2005; 165(20): 2420-2427.
395. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene
polymorphism, plasma angiotensinogen, and risk of hypertension and
ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol
2003; 23(7): 1269-1275.
396. Shahid A, Zuberi SJ, Hasnain N. Lipid pattern in healthy subjects. Pak J
Med Res 1985; 24: 33-37.
397. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR
Methods Appl 1993; 3(2): 120 –121.
398. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW, Mc
Killop JH, Packard CJ. Prvention of coronary heart disease with pravastatin
in men with hyper-cholesteromia. West of Scotland Coronary Prevention
Study Group. N Engl J Med 1995; 333(20): 1301 – 1307.
399. Shi G, Gu CC, Kraja AT, Arnett DK, Myers RH, Pankow JS, Hunt SC, Rao
DC. Genetic effect on blood pressure is modulated by age: the Hypertension
Genetic Epidemiology Network Study. Hypertension 2009; 53(1): 35-41.
400. Shibuki K and Okada D. Endogenous nitric oxide release required for long-
term synaptic depression in the cerebellum. Nature 1991; 349(6307): 326–
328.
401. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa
H, Harada E, Masuda T, Koyama W, Saito Y, Miyamoto Y, Ogawa Y,
Nakao K. Association of the missense Glu298Asp variant of the endothelial
nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol
1998; 31(7): 1506-1510.
402. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS,
McClellan MB. Association in renal insufficiency with treatment and
Bibliography
267
outcomes after myocardial infarction in elderly patients. Ann Intern Med
2002; 137(7): 555-562.
403. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg
NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II
in essential hypertension. J Clin Invest 1983; 72(6): 2115 - 2124.
404. Shoji M, Tsutaya S, Saito R, Takamatu H, Yasujima M. Positive association
of endothelial nitric oxide synthase gene polymorphism with hypertension in
northern Japan. Life Sci 2000; 66(26): 2557-2562.
405. Siegel D, Benowitz N, Ernster VL, Grady DG, Hauck WW. Smokeless
tobacco, cardiovascular risk factors, and nicotine and cotinine levels in
professional baseball players. Am J Public Health 1992; 82(3): 417- 421.
406. Singh RB, Beegom R, Ghosh S, Niaz MA, Rastogi V, Rastogi SS, Singh
NK, Nangia S. Epidemiological study of hypertension and its determinants
in an urban population of north India. J Hum Hypertens 1997; 11(10): 679-
685.
407. Skaric-Juric T. Path analysis of familial resemblance in blood pressure in
Middle Dalmatia, Croatia. Coll Anthropol 2003; 27(1): 229-237.
408. Skrabal F, Aubock J, Hortnagl H. Low sodium/high potassium diet for
prevention of hypertension: probable mechanisms of action. Lancet 1981;
2(8252): 895 - 900.
409. Sookoian S, Castano G, Garcia SI, Viudez P, Gonzalez C, Pirola CJ.
A1166C angiotensin II type 1 receptor gene polymorphism may predict
hemodynamic response to losartan in patients with cirrhosis and portal
hypertension. Am J Gastroenterol 2005; 100(3): 636- 642.
410. Soons KR, Little DN, Harvey J. Cholesterol screening in the elderly:
changing attitudes. Gerontology 1995; 41(1): 57-62.
411. Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F, Corvol P.
Molecular biology of the angiotensin I-converting enzyme: II. Structure-
function. Gene polymorphism and clinical implications. J Hypertens 1993;
11(6): 599–604.
412. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and
cardiovascular disease: an update. Hypertension 2001; 37 (4): 1053–1059.
Bibliography
268
413. Srivastava K, Biswas UK, Narang R, Varghese JJ, Das N. Prevalence of
eNOS Glu298Asp polymorphism in healthy volunteers from a region of
Northern India. Community Genet 2005; 8(3): 180-183.
414. Srivastava K, Sundriyal R, Meena PC, Bhatia J, Narang R, Saluja D.
Association of Angiotensin converting enzyme (insertion/deletion) gene
polymorphism with essential hypertension in Northern Indian subjects.
Genet Test Mol Bio 2012; 16(3): 174-177.
415. Staessan JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F,
Vlietinck R, Fagard R. The deletion/insertion polymorphism of the
angiotensin converting enzyme gene and cardiovascular-renal risk. J
Hypertens 1997; 15(12): 1579- 1592.
416. Staessen JA, Fagard R, Amery A. Life style as a determinant of blood
pressure in the general population. Am J Hypertens 1994; 7(8): 685 - 694.
417. Stamler J, Berkson DM, Dyer A, Lepper MH, Lindberg HA, Paul O,
Mckean H, Rhomberg P, Schoenberger JA, Shekelle RB, Stamler R.
Relationship of multiple variables to blood pressure - findings from four
Chicago epidemiologic studies. Epidemiology and Control of Hypertension
1975; 307. Stratton, New York.
418. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE,
Anastasiadis G, Triposkiadis P, Kyriakidis M. Predicting response to
chronic anti-hypertensive treatment with fosinopril: the role of angiotensin
converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000;
14(4): 427 – 432.
419. Stems RH, Cox M, Feig P, Singer I. Internal potassium balance and the
control of the plasma potassium concentration. Medicine 198l; 60(5): 339-
354.
420. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D,
Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski
J, Brewer A, Singh B, Cohen J; Trials for the Hypertension Prevention
Researcg Group. Long term weight loss and changes in blood pressure:
results of the Trials of Hypertension Prevention, Phase II. Ann Intern Med
2001; 134(1): 1-11.
Bibliography
269
421. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The
angiotensin AT2 receptor mediates inhibition of cell proliferation in
coronary endothelial cells. J Clin Invest 1995; 95(2): 651-657.
422. Sullivan JM and Ratts TE. Hemodynamic mechanisms of adaptation to
chronic high sodium intake in normal humans. Hypertension 1983; 5(6): 814
- 820.
423. Sullivan JM, Ratts TE, Reed SW, Banna A, Riddle JC, Jordan C: Evidence
for altered vascular reactivity in sodium-sensitive young subjects with
borderline hypertension. Am J Med Sci 1984; 288(2): 65 - 73.
424. Sullivan JM, Ratts TE, Taylor JC, Kraus DH, Barton BR, Patrick DR, Reed
SW. Hemodynamic effects of dietary sodium in man: a preliminary report.
Hypertension 1980; 2(4): 506 - 514.
425. Sullivan JM. Borderline hypertension and sodium sensitivity. J Cardiovasc
Pharmacol 1986; 8(5): S31 – S35.
426. Svetkey LP, McKeown SP, Wilson AF. Heritability of salt sensitivity in
black Americans. Hypertension 1996; 28(5): 855-858.
427. Szombathy T, Szalai C, Katalin B, Palicz T, Romics L, Csaszar A.
Association of angiotensin II type 1 receptor polymorphism with resistant
essential hypertension. Clin Chim Acta 1998; 269(1): 91-100.
428. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilatation to acetylcholine in
primary and secondary forms of human hypertension. Hypertension 1993;
21(6): 929-933.
429. Takami S, Katsuya T, Raguki H, Sato N, Nakata Y, Kamitani A, Miki T,
Higaki J, Ogihara T. Angiotensin II type 1 receptor gene polymorphism is
associated with increase of left ventricular mass but not with hypertension.
Am J Hypertens 1998; 11(3): 316– 321.
430. Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T, Haji M, Inagami T,
Furuta H, Gou DF, Nakamuta M, Nawata H. Molecular cloning, sequence
analysis and expression of a cDNA encoding human type 1 angiotensin II
receptor. Biochem Biophys Res Commun 1992; 183(2): 910–916.
Bibliography
270
431. Tamemoto H, Ishikawa SE, Kawakami M. Association of the Glu 298 Asp
polyrnorphism of the eNOS Gene with ischemic heart disease in Japanese
diabetic subjects. Diabetes Res Clin Pract 2008; 80(2): 275-279.
432. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distribution
of coronary aortic atherosclerosis by geographic location, race and sex. Lab
Invest 1968; 18(5): 509 - 526.
433. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R,
Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S; INTERHEART Study
Investigators. Tobacco use and risk of myocardial infarction in 52 countries
in the INTERHEART study: a case-control study. Lancet 2006; 368(9536):
647 - 658.
434. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J.
Intracellular processing of endothelial nitric oxide synthase isoforms
associated with differences in severity of cardiopulmonary diseases:
Cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl
Acad Sci USA 2000; 97(6): 2832-2835.
435. The Fifth Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Expert Group. Arch
Intern Med 1993; 153: 154-86.
436. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II.
The Relationship of reduction in incidence of coronary heart disease to
cholesterol lowering. JAMA 1984; 251(3): 365-374.
437. The Sixth Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;
157(21): 2413 - 2446.
438. Theorell T, de Faire U, Schalling D, Adamson U, Askevold F. Personality
traits and psycho-physiological reactions to a stressful interview in twins
with varying degrees of coronary hear t disease. J Psychosom Res 1979;
23(1): 89-99.
439. Third Report of the National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) final report National Cholesterol
Bibliography
271
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Circulation 2002; 106(25): 3143 - 3421.
440. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ,
Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and
angiotensin II receptor antagonists. Pharmacol Rev 1993; 45(2): 205-251.
441. Tiret L, Blanc H, Ruidavets JB, Arveiler D, Luc G, Jeunemaitre X, Tichet J,
Mallet C, Poirier O, Plouin PF, Cambien F. Gene polymorphisms of the
renin-angiotensin system in relation to hypertension and parental history of
myocardial infarction and stroke: the PEGASE study. Projet d’Etude des
Genes de l’Hypertension Arterielle Severe a moderee Essentielle. J
Hypertens 1998; 16(1): 37– 44.
442. Tobian L Jr. A viewpoint concerning the enigma of hypertension. AmJ Med
1972; 52(5): 595.
443. Tolins JP, Palmer RM, Moncada S, Raij L. Role of endothelium-derived
relaxing factor in regulation of renal haemodynamic responses. Am J
Physiol 1990; 258: H655-H662.
444. Tomei F, Fantini S, Tomao E, Baccolo TP, Rosati MV. Hypertension and
chronic exposure to noise. Arch Environ Health 2000; 55(5): 319-325.
445. Touyz RM and Schiffrin EL. Increased generation of superoxide by
angiotensin II in smooth muscle cells from resistance arteries of
hypertensive patients: role of phospholipase D-dependent NAD(P)H
oxidase-sensitive pathways. J Hypertens 2001; 19(7): 1245–1254.
446. Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH,
Selwyn AP, Alexander RW, Ganz P. Epicardial coronary artery responses to
acetylcholine are impaired in hypertensive patients. Circ Res 1992; 71(4):
776-781.
447. Tsai CT, Fallin D, Chiang FT, Hwang JJ, Lai LP, Hsu KL, Tseng CD, Liau
CS, Tseng YZ. Angiotensinogen gene haplotype and hypertension:
interaction with ACE gene I allele. Hypertension 2003; 41(1): 9-15.
448. Tsujita Y, Baba S, Yamauchi R, Mannami T, Kinoshita M, Yamamoto R,
Katsuya T, Higaki J, Ogihara T, Ogata J, Iwai N. Association analyses
Bibliography
272
between genetic polymorphisms of endothelial nitric oxide synthase gene
and hypertension in Japanese: The Suita Study. J Hypertens 2001; 19(11):
1941–1948.
449. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A,
Kawaguchi Y, Hosoya T, Igari J. Evidence of association of the ecNOS gene
polymorphism with plasma NO metabolite levels in humans. Biochem
Biophys Res Commun 1998; 245(1): 190-193.
450. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes P, Alexander
RW, Harrison DG, Medford RM. Angiotensin II induces vascular cell
adhesion molecule-1 expression in rat vasculature; A potential link between
the renin-angiotensin system and atherosclerosis. Circulation 1999; 100(11):
1223-1229.
451. Ueda S, Meredith PA, Morton JJ, Connell JM, Eliott HL. ACE (I/D)
geneotype as a predictor of the magnitude and duration of the response to an
ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98(20): 2148
– 2153.
452. Ukoh VA and Obasohan AO. Salt intake, red cell and plasma electrolytes in
hypertensive and normotensive Nigerians. Nig J Physiol Sci 1992; 8: 42-48.
453. Ukoh VA and Oforofuo IA. Plasma lipid profiles in Nigerians with normal
blood pressure, hypertension and other acquired cardiac conditions. East Afr
Med J 2007; 84(6): 264 - 270.
454. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable
number of tandem repeats in the endothelial constitutive nitric oxide
synthase gene with essential hypertension in Japanese. Am J Hypertens
1998; 11(1): 125-128.
455. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric
oxide on peripheral arteriolar tone in man. Lancet 1989; 2(8670): 997–1000.
456. Vartiainen E, Pekkanen J, Koskinen S, Jousilahti P, Salomma V, Puska P.
Do changes in cardiovascular risk factors explain the increasing
socioeconomic difference in mortality from ischaemic heart disease in
Finland? J Epidemiol Community Health 1981; 52(7): 416-419.
Bibliography
273
457. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of
frequency of progression to hypertension in non-hypertensive participants in
the Framingham Heart Study: a cohort study. Lancet 2001; 358(9294):
1682-1686.
458. Vasku A, Soucek M, Znojil V, Rihacek I, Tschoplova S, Strelcova L, Cidl
K, Blazkova M, Hajek D, Holla L, Vacha J. Angiotensin I-converting
enzyme and angiotensinogen gene interaction and prediction of essential
hypertension. Kidney Int 1998; 53(6): 1479 –1482.
459. Vassilikioti S, Doumas M, Douma S, Petidis K, Karagiannis A, Balaska K,
Vyzantiadis A, Zamboulis C. Angiotensin converting enzyme gene
polymorphism is not related to essential hypertension in a Greek population.
Am J Hypertens 1996; 9(7): 700-702.
460. Verdecchia P, Staessen JA, White WB, Imai Y, O’Brien ET. Properly
defining white coat hypertension. Eur Heart J 2002; 23(2): 106-109.
461. Waern V and Aberg H. Blood pressure in 60 year old men. Findings in a
health survey and some comparisons with 50 year old men in the same
community. Acta Med Scan 1979; 266(1): 99 - 105.
462. Wakabayashi I and Hatake K. Effects of ethanol on the nervous and vascular
systems: the mechanisms of alcohol-induced hypertension. Nihon Eiseigaku
Zasshi. 2001; 55(4): 607- 617.
463. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function
change in hypertensive members of the Multiple Risk Factor Intervention
Trial. Racial and treatment effects. The MRFIT Research Group. JAMA
1992; 268(21): 3085–3091.
464. Walker WG, Whelton PK, Saito H, Russel RP, Hermann J. Relation
between blood pressure and renin, renin substrate, angiotensin II,
aldosterone and urinary sodium and potassium in 574 ambulatory subjects.
Hypertension 1979; 1(3): 287–291.
465. Wallace JP. Exercise in hypertension: A clinical review. Sports Med 2003;
33(8): 585 – 598.
Bibliography
274
466. Wang J, Dudley D, Wang XL. Haplotype-specific effects on endothelial NO
synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler
Thromb Vasc Biol 2002; 22(5): e1–e4.
467. Wang JG and Staessen JA. Genetic polymorphisms in the renin-angiotensin
system: relevance for susceptibility to cardiovascular disease. Eur J
Pharmacol 2000; 410(2): 289-302.
468. Wang WY, Zee RY, Morris BJ. Association of angiotensin II type 1 receptor
gene polymorphism with essential hypertension. Clin Genet 1997a; 51(1):
31- 34.
469. Wang XL, Mahaney MC, Sim AS, Wang J, Wang J, Blangero J, Almasy S,
Badenhop RB, Wilcken DE. Genetic contribution of the endothelial
constitutive nitric oxide synthase gene to plasma nitric oxide levels.
Arterioscler Thromb Vasc Biol, 1997b, 17(11): 3147–3153.
470. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-
dependent risk of coronary artery disease associated with a polymorphism of
the endothelial nitric oxide synthase gene. Nat Med 1996; 2(1): 41–45.
471. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J.
Genotype dependent and cigarette specific effects on endothelial nitric oxide
synthase gene expression and enzyme activity. FEBS Lett 2000; 471: 45–50.
472. Wang Y and Marsden PA. Nitric oxide synthases: biochemical and
molecular regulation. Curr Opin Nephrol Hypertens 1995; 4(1): 12–22.
473. Wang Y, Kikuchi S, Suzuki H, Nagase S, Koyama A. Endothelial nitric
oxide synthase gene polymorphism in intron 4 affects the progression of
renal failure in non-diabetic renal diseases. Nephrol Dial Transplant 1999;
14(12): 2898 – 2902.
474. Wannamethee G, Whincup PH, Shaper AG, Lever AF. Serum sodium
concentration and risk of stroke in middle-aged males. J Hypertens 1994;
12(8): 971–979.
475. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C,
Farrington PF, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki M,
Corvol P, Lifton RP, Lalouel JM. A molecular variant of angiotensinogen
associated with preeclampsia Nat Genet 1993; 4(1): 59 – 61.
Bibliography
275
476. Watkin DM, Froeb HG, Hatch FT, Gutman AB. Effects of diet in essential
hypertension. II. Results with unmodified Kempner rice diet in 50
hospitalized patients. Am J Med 1950; 9(4): 441 - 493.
477. Watt GC, Harrap SB, Foy CJ, Holton DW, Edwards HV, Davidson HR,
Connor JM, Lever AF, Fraser R. Abnormalities of glucocorticoid
metabolism and the renin-angiotensin system: a four-corners approach to the
identification of genetic determinants of blood pressure. J Hypertension
1992; 10(5): 473 - 482.
478. Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JA. Therapeutic
implications of human endothelial nitric oxide synthase gene polymorphism.
Trends Pharmacol Sci 2001; 22(7): 361–368.
479. Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and
exercise responses in obese and lean hypertensive patients. J Am Coll
Cardiol 2001; 37(1): 169-174.
480. Wei D, Shan J, Chen Z, Shi Y. The G894T mutation of the endothelial nitric
oxide synthase gene is associated with coronary atherosclerotic heart disease
in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002; 19(6): 471-474.
481. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions
and characteristics of sodium sensitivity and blood pressure resistance.
Hypertension 1986; 8(6): 127-134.
482. Weinberger MH. Salt sensitivity: does it play an important role in the
pathogenesis and treatment of hypertension? Curr Opin Nephrol Hypertens
1996; 5(3): 205-208.
483. Weir MR and Henrich WL. Theoretical basis and clinical evidence for
differential effects of angiotensin-converting enzyme inhibitors and
angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens
2000; 9(4): 403–411.
484. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ.
The effects of oral potassium on blood pressure: meta-analysis of
randomized controlled clinical trials. JAMA 1997; 227(20): 1624-1632.
485. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344(8915): 101-
106.
Bibliography
276
486. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood
pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med
2002; 136(7): 493-503.
487. Whitescarver SA, Holtzclaw BJ, Downs JH, Ott CE, Sowers JR, Kotchan
TA. Effect of dietary chloride on salt-sensitive and renin-dependent
hypertension. Hypertension 1986; 8(1): 56-61.
488. Wiinber N, Hoegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen
PE, Svendsen TL, Kampmann JP, Madsen NH, Bentzon MW. 24-h
ambulatory blood pressure in 352 normal Danish subjects, related to age and
gender. Am J Hypertens. 1995; 8(10): 978 –986.
489. Williams GH and Hollenberg NK. Are non-modulating patients with
essential hypertension a district subgroup? Implications for therapy. Am J
Med 1985; 79(3C): 3 - 9.
490. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ,
Barlow GK, Stephenson SH, Lalouel JM, Kuida H. Familial dyslipidemic
hypertension: Evidence from 58 Utah families for a syndrome present in
approximately 12% of patients with essential hypertension. JAMA 1988;
259(24): 3579-3586.
491. World Health Organization - Hypertension and coronary heart disease:
classification and criteria for epidemiological studies. WHO Tech Rep Ser
1959; 58(168): 1 - 28.
492. World Health Organization. Training for Mid-level Managers: The EPI
Coverage Survey. Geneva: WHO Expanded Programme on Immunization,
1991. WHO/EPI/MLM/91.10.
493. Worthington MG, Wendt MC, Opie LH. Sodium transport in hypertension:
assessment of membrane-associated defects in South African black and
white hypertensives. J Hum Hypertens 1993; 7(3): 291-297.
494. Xu Q, Wang YH, Tong WJ, Gu ML, Wu G, Buren B, Liu YY, Wang J, Li
YS, Feng H, Bai SL, Pang HH, Huang GR, Fang MW, Zhang YH, Wu ZL,
Qiu CC. Interaction and relationship between angiotensin converting
enzyme gene and environmental factors predisposing to essential
Bibliography
277
hypertension in Mongolian population of China. Biomed Environ Sci 2004;
17(2):177-186.
495. Yoshida H, Mitarari T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R,
Kawaguchi Y, Kubo H, Ichikawa I, Sakai O. Role of the deletion of
polymorphism of the angiotensin converting enzyme gene in the progression
and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;
96(5): 2162 - 2169.
496. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Ogawa H, Kugiyama
K, Saito Y, Miyamoto Y, Ogawa Y, Kaneshige T, Hiramatsu H, Yoshioka
T, Kamitani S, Teraoka H, Nakao K. Genetic risk factors for coronary artery
spasm: significance of endothelial nitric oxide synthase gene T-786→C and
missense Glu298Asp variants. J Investig Med 2000; 48(5): 367 – 374.
497. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama
S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K. A
missense Glu298Asp variant in the endothelial nitric oxide synthase gene is
associated with coronary spasm in the Japanese. Hum Genet 1998; 103(1):
65–69.
498. Yusuf S, Reddy KS, Ounpuu S, Anand S. Global burden of cardiovascular
diseases. Part I: general considerations, the epidemiologic transition, risk
factors, and impact of urbanisation. Circulation 2001; 104(22): 2746–2753.
499. Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism
of the angiotensin I-converting enzyme gene with essential hypertension.
Biochem Biophys Res Comm 1992; 184(1): 9–15.
500. Zee RY, Ridker PM, Stampfer MJ, Hennekens CH, Lindpaintner K.
Prospective evaluation of the angiotensin-converting enzyme
insertion/deletion polymorphism and the risk of stroke. Circulation 1999;
99(3): 340–343.
501. Zhang S, Day I, Ye S. Nicotine induced changes in gene expression by
human coronary artery endothelial cells. Atherosclerosis 2001; 154(2): 277–
283.
502. Zingone A, Dominijanni A, Mele E, Marasco O, Melina F, Minchella P,
Quaresima B, Tiano MT, Gnasso A, Pujia A, et al. Deletion polymorphism
Bibliography
278
in the gene for angiotensin converting enzyme in association with elevated
fasting blood glucose levels. Hum Genet 1994; 94(2): 207–209.
503. Zintzaras E, Kitsios G, Stefanidis I. Endothelial NO synthase gene
polymorphisms and hypertension: a meta-analysis. Hypertension 2006;
48(4): 700-710.
